

CURRICULUM VITAE
ROBERT W. YEH, M.D., M.Sc, M.B.A.

Date Prepared: 8/4/2020

Office Address

Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology
Beth Israel Deaconess Medical Center
375 Longwood Avenue, 4th Floor
Boston, MA 02215

Home Address

17 Ascenta Terrace, Newton, MA 02465

Work Phone: (617) 632-7653
Work Email: ryeh@bidmc.harvard.edu
Work Fax: (617) 632-7698

Place of Birth: Los Angeles, CA

Education

9/92 – 6/96	BA, Human Biology (Honors and Distinction, Phi Beta Kappa)	Stanford University
9/97 – 6/98	MSc, Health Policy, Planning and Financing	London School of Economics/Hygiene and Tropical Medicine (Joint Degree)
9/98 – 10/99	MBA (<i>Distinction</i>)	Oxford University, Said Business School
9/99 – 6/03	MD	Harvard Medical School
7/08 – 6/09	Certificate in Clinical Research, Epidemiology and Biostatistics	University of California, San Francisco

Postdoctoral Training

7/03 – 6/04	Intern, Internal Medicine	Massachusetts General Hospital
7/04 – 6/06	Resident, Internal Medicine	Massachusetts General Hospital
7/06 – 6/09	Fellow, Cardiovascular Disease	University of California, San Francisco
7/09 – 6/10	Fellow, Interventional Cardiology	Massachusetts General Hospital

Faculty Academic Appointments

7/10 – 10/12	Instructor in Medicine	Harvard Medical School
10/12 – 2/16	Assistant Professor of Medicine Investigator Criteria	Harvard Medical School
2/16 –	Associate Professor of Medicine Investigator Criteria	Harvard Medical School
12/18 –	Katz-Silver Family Endowed Chair in Cardiovascular Outcomes Research	Harvard Medical School

Appointments at Hospitals/Affiliated Institutions

7/10 – 12/12	Assistant in Medicine,	Massachusetts General Hospital
--------------	------------------------	--------------------------------

12/12 – 11/15	Assistant Physician in Medicine	Massachusetts General Hospital
7/10 – 11/15	Affiliated Faculty Member	Mongan Institute for Health Policy
11/15 –	Attending Physician	Beth Israel Deaconess Medical Center

Other Professional Positions

2014 – 2017	Coronary Artery Disease Medical Scientific Advisory Board	Abbott Vascular
2015 – 2018	Chronic Total Occlusion Scientific Advisory Board	Abbott Vascular
2015 –	Chronic Total Occlusion Scientific Advisory Board	Boston Scientific
2016 –	Executive Physician Council	Boston Scientific
2017 –	Interventional Cardiology Scientific Advisory Board	Medtronic
2020 –	Special Government Employee, Cardiac Devices Advisory Panel	Center for Devices and Radiologic Health, US Food and Drug Administration

Major Administrative Leadership Positions

Local

2007 – 2008	Chief Cardiology Fellow	University of California, San Francisco
2010 – 2011 2011 –	Associate Medical Director, Trial Design Medical Director, Trial Design	Harvard Clinical Research Institute Harvard Clinical Research Institute/Baim Institute for Clinical Research
2013 – 2014	Project Leader, AMI Care Redesign, Intraprocedural Subgroup	Massachusetts General Hospital
2013 - 2015	Co-Director, MGH Chronic Total Occlusion Program	Massachusetts General Hospital
2013 – 2015	Co-Chair, Partners Long Term Outcomes Workgroup/Cardiovascular Analytics Collaborative	Partners Healthcare
2014 – 2015	Associate Medical Director, Cardiac Intensive Care Unit	Massachusetts General Hospital
2015 – 2017	Director, Chronic Total Occlusion PCI Program	Beth Israel Deaconess Medical Center
2015 –	Director, Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology - Founding Director of center devoted to outcomes research in 3 primary areas – health policy evaluation, comparative effectiveness research, and use of novel sources of data for risk prediction - Hired and supervise full time junior faculty, statisticians, administrative staff, trainees. - Created an endowed scholar position to support junior faculty with the Center	Beth Israel Deaconess Medical Center
2017 – 2017 –	Director of Complex Coronary Intervention Associate Chief, Interventional Cardiology	Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center

National

2012 – 2013	Vice Chair, Carotid Artery Revascularization and Endarterectomy Registry, Research and Publications Committee	National Cardiovascular Data Registry
2012 – 2013	Chairman, Risk Modeling Panel, Carotid Artery Revascularization and Endarterectomy Registry	National Cardiovascular Data Registry
2015 –	Chairman, Rapid Registry Response (RRR) /Research To Practice (R2P) Initiative	National Cardiovascular Data Registry

Committee ServiceLocal

2005 – 2006, 2010	Intern Selection Committee	Massachusetts General Hospital
2008 – 2009	Cardiology Fellowship Selection Committee	University of California, San Francisco
2010 – 2015	Long Term Outcomes Steering Committee	Partners Healthcare
2011 – 2013	Partners AMI Care Redesign Committee	Partners Healthcare
2012 – 2013	Integrated Care Steering Committee for Peripheral Arterial Disease	Institute for Heart, Vascular and Stroke Care Massachusetts General Hospital
2012 – 2013	MGH/MGPO Strategic Planning – Episodic Care Team	Massachusetts General Hospital
2009 – 2015	Interventional Cardiology Fellowship Selection Committee	Massachusetts General Hospital
2010 – 2015	STEMI Quality Improvement Committee	Massachusetts General Hospital
2013 – 2015	Partners Health System Cardiac Quality Leaders Committee	Partners Healthcare
2010 – 2015	Executive Committee, Publications Committee The Dual Antiplatelet Therapy Study	Harvard Clinical Research Institute
2011 – 2015	Advisory Committee on Clinical Epidemiology and Outcomes Research, Scholars in Medicine Program	Harvard Medical School
2016 -	Cardiology Fellowship Selection Committee	Beth Israel Deaconess Medical Ctr

Regional

2012 – 2016	Exceptional Risk Adjudication Committee, Massachusetts Public Reporting Program	Massachusetts Data Analysis Center Harvard Medical School
-------------	---	--

National

2013 – 2014	Research and Publications Committee and Transitional Working Group, National Cardiovascular Data Registry - Peripheral Vascular Intervention (PVI) Registry	
-------------	---	--

2014 – 2016	Steering Committee, National Cardiovascular Data Registry – Peripheral Vascular Intervention (PVI) Registry	
2012 – 2015 2016 –	Abstract Selection Committee Scientific Program Committee	Transcatheter Cardiovascular Therapeutics Conference
2014 – 2019	Publications Committee (Multicenter Clinical Trial for Chronic Total Occlusion PCI)	OPEN CTO Registry
2016 – 2019	Steering Committee (Multicenter single arm trial of short duration antiplatelet therapy after treatment with Synergy coronary stent)	EVOLVE – Short DAPT Trial
2016 – 2018	Member, American College of Cardiology – Symphony Health Solutions Linked Dataset Expert Panel	National Cardiovascular Data Registry
2016 –	Steering Committee (Multicenter registry of patients with multivessel coronary disease declined for cardiac surgery)	OPTIMUM Registry
2019 –	Steering Committee (Multicenter trial of CT-FFR vs. standard of care for evaluation of stable coronary disease)	PRECISION Trial
<u>International</u>		
2013 – 2014	Coronary Artery Disease Working Group, International Consortium for Health Outcomes Measurement	
2018 – 2020	High Bleeding Risk Working Group	Academic Research Consortium

Professional Societies

American College of Cardiology:

2006 –	Member	
	2012 –	Fellow of the College (F.A.C.C)
2011 –	American College of Cardiology Scientific Sessions Academic Planning Committee, Quality of Care and Outcomes Research Section, 2011 – 2013 Abstract Selection leader, 2013	
	TCT@ACC (Interventional Section) Abstract Selection Committee 2012 - 2013	
	Scientific Sessions Program Committee, 2016 – 2018 Subgroup Lead, Interventional Cardiology: Quality, Economics and Policy.	

American Heart Association:

2006 –	Member	
	2008 –	Member, Council on Quality of Care and Outcomes Research
	2011 –	Member, Council on Epidemiology and Prevention
	2013 –	Fellow of the American Heart Association (F.A.H.A)
2011 – 2013	Writing Committee, American Heart Association Scientific Statement on Risk Adjustment for the Study of Stroke Outcomes	
2013 – 2015	Early Career Committee, Council on Epidemiology and Prevention, American Heart Association	
2013 – 2016	American Heart Association Statistics Committee, Writing Group	

2013 – 2017 Committee on Scientific Sessions Program (CSSP) of the American Heart Association

Society for Cardiovascular Angiography and Interventions

2012 – 2015 Member
2012 Fellow (F.S.C.A.I.)

Grant Review Activities

2011 –	Grant Review, HMS Scholars in Medicine	Standing member, Harvard Medical School
2014	Tosteson/Fund for Medical Discovery (FMD), Executive Committee on Research	Massachusetts General Hospital
2016	Grant Review, Population Health and Outcomes Research	American Heart Association
2018 - 2019	Grant Review, Special Emphasis Panel Single Center Clinical Trials (R61/R33) Meeting 1: 2018/05 ZHL1 CSR-G (M1) Meeting 2: 2018/10 R61/R33/UG3 review	National Heart, Lung, and Blood Institute
2019	Grant Review, Clinical Trials Review Committee CTLR JA1, October 24-25, 2019	National Heart, Lung, and Blood Institute

Editorial Activities

Editorial Board

Associate Editor, Editorial Board, Circulation: Cardiovascular Quality and Outcomes, 2013 – present
Editorial Board, Circulation, 2016 - 2018
International Advisory Board, Heart, January 2014 – 2015
Editorial Board, Coronary Artery Disease, June 2014 - 2016

Ad hoc Reviewer

American Heart Journal
American Journal of Cardiology
Annals of Internal Medicine
Archives of Internal Medicine/JAMA Internal Medicine
British Medical Journal
Catheterization and Cardiovascular Interventions
Coronary Artery Disease
Circulation
Circulation: Cardiovascular Interventions
Circulation: Cardiovascular Quality and Outcomes
European Society of Cardiology, National Guidelines
Health Affairs
Health Service Research
Heart
JACC: Cardiovascular Interventions
JAMA
Journal of the American College of Cardiology
Journal of the American Heart Association
Journal of Invasive Cardiology
New England Journal of Medicine

Honors and Prizes

1992	National Merit Scholar, President's Award	Stanford University
1993	G. Craig Prize for writing in History	Stanford University
1996	Deans' Award for academic achievement	Stanford University
1996	Firestone Medal for Undergraduate Research	Stanford University
1996	Phi Beta Kappa	Stanford University
1997	British Marshall Scholarship	British Government
1998	Director's Award for Academic Excellence	Oxford University
1998	Starting outside hitter, Volleyball (Blues team), '98-'99 season	Oxford University
2000	Paul and Daisy Soros Fellowship	Open Society Institute
2006	Senior Resident Teaching Award	Massachusetts General Hospital
2008	Western Affiliate Postdoctoral Fellow Grant (declined)	American Heart Association
2008	Future Leaders in CV Medical Research Grant	Schering-Plough Corp.
2011	Thomas J. Linnemeier Young Investigator Award	Cardiovascular Research Foundation
2012	National Clinical Research Program Grant	American Heart Association
2013	SPARK Grant, Institute for Heart, Vascular and Stroke Care	Massachusetts General Hospital
2013	Hassenfeld Scholar, Institute for Heart, Vascular and Stroke Care	MGH
2015	Young Physician-Scientist Award	American Society for Clinical Investigation (ASCI)
2018	Harvard Medical School Young Mentor Award	Harvard Medical School

Report of Funded and Unfunded Projects

Past Funded Projects

(Yeh, Robert; Go, Alan) 07/01/2008 – 06/30/2009
 Future Leaders in CV Medical Research Grant Role: Principal Investigator

Temporal Trends in the Incidence, Presentation and Outcomes of Acute Myocardial Infarction

The major goal of the study was to characterize recent temporal trends in the epidemiology of acute myocardial infarction within the Kaiser Permanente of Northern California member population, assess the impact of anti-ischemic medications on myocardial infarction incidence and disease presentation, and evaluate improvements in patient outcomes.

(Yeh, Robert) 07/01/2008 – 09/30/2013
 NIH Loan Repayment Award Role: Principal Investigator

Loan Repayment only, no direct costs

Integrating Predictive Models into Routine Care of Patients Undergoing Percutaneous Coronary Intervention

The primary goal of this research is to apply an innovative information technology infrastructure that can translate complex clinical prediction models to the bedside at the time of informed consent to guide patients and clinicians in the pursuit of safe and effective care. The proposed research will move activities in the cardiac catheterization laboratory toward the Institute of Medicine's goal of delivering care that is safe, effective and patient-centered

12CRP9010016 (Yeh, Robert) 01/01/2012 – 07/01/2014
 American Heart Association Role: Principal Investigator

Identifying Strategies to Reduce Readmissions After Percutaneous Coronary Intervention

The primary goals of the research are to identify predictors of short-term readmission after PCI, quantify hospital variation in risk-standardized 30-day readmission rates, and assess modifiable differences in quality of care that explain such variation.

Hassenfeld Scholars Program (Yeh, Robert) 8/1/2013 – 10/31/2015
 Institute for Heart, Vascular and Stroke Care, MGH Role: Principal Investigator

Strategies to Enhance the Efficacy and Efficiency of Cardiovascular Device Utilization

This project seeks to study existing patterns of medical device and therapy utilization for the treatment of cardiovascular disease, and develop strategies that can improve both their effectiveness and cost-effectiveness based on prospective quantification of treatment benefit.

- Partners Cardiovascular Analytics Collaborative (Yeh, Robert) 10/1/2010 – 9/30/2015
Partners Healthcare Role: Principal Investigator
Optimizing Long-Term Outcomes after Cardiovascular Procedures
This collaborative project renewed annually is devoted to studying hospital and physician variation in the performance and outcomes of cardiovascular procedures (PCI and Cardiac surgery), assess factors associated with poor outcomes, and identify targets for improving procedural outcomes and value.
- (Mauri, Laura; Kereiakes Dean) 07/01/2010 – 11/01/2015
Abbott Vascular, Boston Scientific, Cordis Corporation, Medtronic Vascular, Bristol-Meyers
Squibb, Sanofi-Aventis, Eli Lilly, Daichii Sankyo Role: Co-investigator, Executive
The Dual Antiplatelet Therapy (DAPT) Study and Publication Committees
This was an international multi-center randomized clinical trial comparing 12 months vs. 30 months of treatment with dual antiplatelet therapy in more than 25,000 patients undergoing percutaneous coronary intervention. The study was mandated by the US FDA. I am a member of the study leadership, serving as Medical Director, Global Medical Monitor, and a member of the Executive and Publication Committees.
- SPARK Grant (Yeh, Robert; Shaw, Stanley) 4/1/2013 – 10/31/2015
Institute for Heart, Vascular and Stroke Care, MGH Role: Co-PI
Harnessing the Electronic Medical Record for Risk Prediction and Clinical Decision Support in Coronary and Vascular Intervention
This study seeks to develop and validate models predicting adverse events after coronary and carotid revascularization using information extracted from the structured and unstructured data from the electronic medical record.
- (Yeh, Robert) 7/1/2015 – 10/31/2015
Boehringer-Ingelheim Role: Site PI
RE-DUAL PCI: Study in Non-Valvular Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
Randomized clinical trial comparing the use of dabigatran in combination with P2Y12 inhibition compared to triple therapy with aspirin, P2Y12 inhibition and warfarin in patients with atrial fibrillation undergoing PCI. Project transferred to another PI upon leaving institution.
- (Yeh, Robert) 8/1/2015 – 10/31/2015
Biotronik Role: Site PI
A Clinical Assessment of the Safety and Effectiveness of the Orsiro Sirolimus-eluting Coronary Stent System in the Treatment of Subjects with up to Three De Novo or Restenotic Coronary Artery Lesions – BIOFLOW V.
Randomized clinical trial comparing a novel drug-eluting stent with bioresorbable polymer compared to a durable polymer stent in patients undergoing PCI. Project transferred to another PI upon leaving institution.
- Innovation Pilot Grant (Yeh, Robert) 5/1/2015 – 4/30/2016
MGH Department of Medicine Role: Principal Investigator/Co-
Investigator
Integration of Predictive Models to Support Clinical Decision Making in the Routine Care of Patients Undergoing Percutaneous Coronary Intervention
This study seeks to leverage a novel tool that can integrate multivariable risk prediction at the point of care for patients undergoing percutaneous coronary intervention to support individualized clinical decision making and improved transparency of informed consent. The tool is supported by Natural Language Processing (NLP) software that can mine the electronic medical record in real time. The impact of the tool on physician decision making, patient outcomes, and costs of care will be assessed through a quasi-experimental (“difference in differences” approach). Role transferred to Co-Investigator after leaving institution.
- ISRCAR00001 (Yeh, Robert) 5/1/2016 – 4/30/2017
Boston Scientific Role: Principal Investigator
Assessing the Cost Effectiveness of 3 vs. 12 Months of Dual Antiplatelet Therapy After PCI
The study seeks to compare outcomes, costs and cost-effectiveness of treatment with 3 months of dual antiplatelet therapy after percutaneous coronary intervention with a bioabsorbable polymer stent vs. durable polymer drug-eluting stent.

- (Yeh, Robert) 10/21/2016 – 12/31/2017
 Abiomed, Inc. Role: Principal Investigator
Physician Perceptions on Risk Avoidance Behavior for High Risk Percutaneous Coronary Intervention in Public Reporting and Non-Public Reporting States
 The study is a national survey of interventional cardiologists exploring physician tolerance of risk, and its influence on potential risk avoidant behavior in performing percutaneous coronary intervention in high-risk patients. The study compared responses among patients practicing in states with and without mandatory public reporting of procedural mortality.
- Innovation Grant (Yeh, Robert) 10/1/2016 – 9/30/2017
 Center for Healthcare Delivery Science, Beth Israel Deaconess Role: Principal Investigator
Patient Reported Outcomes Assessment After Percutaneous Coronary Intervention
 Pilot program to collect longitudinal patient reported health status measures such as angina status during the routine course of clinical care using a combination of tablet-based and web surveys, to improve the assessment of procedural effectiveness and quality of care. Collaborative research involving cardiac catheterization laboratory staff, clinical information services, and the Smith Center for Outcomes Research.
- K23HL118138 (Yeh, Robert) 9/01/2013 – 4/30/2018
 NIH/National Heart, Lung and Blood Institute Role: Principal Investigator
Balancing the Risks of Bleeding and Ischemia in Percutaneous Coronary Intervention
 The goal of this study is to identify patient-specific risks of bleeding and ischemia, develop risk prediction models that integrate these disparate risks, and identify patient groups who derive the greatest vs. least benefit from extended duration dual antiplatelet therapy after coronary stenting. The results of the study will enable individualized assessments of the tradeoffs between benefits and risks of different antithrombotic regimens in patients with cardiovascular disease.
- (Yeh, Robert) 1/1/2017 – 12/31/2018
 Abiomed, Inc. Role: Principal Investigator
National Trends, Hospital Variation, and Outcomes in Utilization of Mechanical Circulatory Support for Cardiogenic Shock.
 The goals of this investigator-initiated study are to examine overall and regional trends in the use of in-hospital non-durable MCS (including ECMO) for cardiogenic shock using a national claims database. Predictors of non-durable MCS use for cardiogenic shock will be identified. Hospital variation will be examined and used to inform the impact of MCS use on in-hospital mortality.
- ISRCAR000082 (Yeh, Robert) 12/1/2016 – 1/1/2019
 Boston Scientific Role: Principal Investigator
Weighing the Potential Late Benefits versus Early Hazard Associated with Bioresorbable Scaffolds in Percutaneous Coronary Intervention
 This investigator-initiated study uses decision analysis to quantify the reduction in late adverse events necessary to offset the early increase in stent thrombosis observed for bioresorbable scaffolds (BRS) among patients undergoing percutaneous coronary intervention with either a BRS or a current-generation drug-eluting stent (DES).
- (Hsue) 12/1/2017 – 5/30/2019
 University of California San Francisco Role: Site PI
Management of acute coronary syndrome among HIV+ patients
 The major goal is to retrospectively review the inpatient management of ACS for HIV-infected versus non-infected adults, differences in their clinical presentation and subsequent care may be identified. This in turn will guide future interventions to improve outcomes of CV disease for this population.
- Boston Scientific (Kirtane, A) 03/01/2016 – 10/01/2019
The EVOLVE – Short DAPT Study Role: Steering Committee
 Post-marketing study evaluating the safety and efficacy of the Synergy bioresorbable polymer drug-eluting stent, among patients at high risk for bleeding. Enrolled patients will be treated with an abbreviated duration of dual antiplatelet therapy for 3 months.

(Grantham, Kandzari)
Boston Scientific
OPTIMUM Registry

9/2015 – completion of study
Role: Site PI and Steering Committee

Prospective registry of patients with multivessel coronary artery disease turned down for cardiac surgery. The primary goal of the study is to examine treatment patterns, long term patient-reported health status, and clinical outcomes among this high risk patient population. The results will be used to inform event rates and feasibility for future randomized trials among patients with coronary disease ineligible to receive cardiac surgery.

(Yeh, Robert)
Abbott Cardiovascular Systems, Inc.

4/6/2018 – 4/5/2020
Role: Principal Investigator

Long-term Outcomes and Resource Utilization Associated with Target Vessel Failure

This investigator-initiated study aims to evaluate the frequency of ISR-PCI (in-stent restenosis - percutaneous coronary intervention) in a large representative sample in the US, the patient and procedural characteristics of these procedures, and the long-term outcomes and cost associated with ISR-PCI.

(Yeh, Robert)
Astra Zeneca

10/2017 – 6/2020
Role: Principal Investigator

Rates and Predictors of Incident Heart Failure After Myocardial Infarction.

The objectives of the project are to estimate the cumulative incidence of new heart failure hospitalization after presentation with acute myocardial infarction among patients without prior heart failure. Secondary goals include identifying predictors of incident heart failure, and examine the impact of medication adherence with subsequent admissions and mortality.

Current Funded Projects

Richard A. and Susan F. Smith Center for Outcomes
Research in Cardiology (Yeh, Robert)

11/1/2015 –
Role: Founding Director/PI

Center for the Health Policy Evaluation, Comparative Effectiveness Research and Patient-Centered Outcomes Investigation

The Center seeks to apply the most rigorous scientific methods to understand and transform the way healthcare is delivered for the treatment of cardiovascular disease. will create specific focus areas in 1) the evaluation of health policy and its effect on patient outcomes, quality of care and cost, 2) the evaluation of treatments and devices for patients across the entire spectrum of cardiovascular conditions, and 3) the integration of novel sources of information about patient health and behavior to enable the delivery of personalized health care. Our commitment to discovery in these areas will create innovative solutions to the challenges created by growing health care costs, expanding technological capabilities, and increasing patient complexity.

R01HL136708 (Yeh, Robert)
NIH/National Heart, Lung, and Blood Institute

5/1/2017 – 3/31/2022
Role: Principal Investigator

Use of Registries, Claims and Health System Data to Enhance the Evaluation of Cardiovascular Therapies in Clinical Trials

The goals of this proposal are to evaluate whether alternative sources of data from hospital claims and insurers can be used to augment data collected in clinical trials to evaluate the effectiveness new medical therapies, identify patients who benefit the most (or least) from treatment (heterogeneity of treatment effect), and to assess whether clinical trial data are applicable to patients seen in the community (generalizability).

R01HL139837-01 (Moran, Bress, Weintraub)
NIH/NHLBI

12/01/2017 – 11/30/2021
Role: Co-Investigator, SubAward PI

Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)

The Optimize-SPRINT study is an ancillary study to the landmark SPRINT trial that compared intensive versus standard blood pressure-lowering treatment. Optimize-SPRINT will use predictive modeling and health economic methods to facilitate selection of optimal population groups and individual patients for intensive high blood pressure treatment.

(Mehran)
Abbott Vascular

9/2018 – completion of trial
Role: Site PI

XIENCE 90/28 Short DAPT Trials

Prospective single-arm trial to evaluate the safety of 90 days of dual antiplatelet therapy after percutaneous

coronary intervention with the Xience drug-eluting stent. Xience 28 followed Xience 90 to assess the safety of 28 days of dual antiplatelet therapy after percutaneous coronary intervention.

(Kereiakes)
Shockwave Medical
DISRUPT CAD Trial
US FDA IDE pivotal trial for the use of intravascular lithotripsy for the treatment of calcific de novo coronary artery disease.

4/2019 – completion of trial
Role: Site PI

(Secemsky/Yeh)
Bard, Boston Scientific, Cook Medical, Medtronic, Phillips
Safety Assessment of Femoropopliteal Endovascular treatment with Paclitaxel-coated Devices (SAFE-PAD Study)

10/1/2019 – 6/30/2023
Role: Co-Principal Investigator

Multi-industry sponsored safety assessment of paclitaxel-coated balloons and paclitaxel-eluting stents used in peripheral vascular intervention. The study was conceived or and designed by the Co-PIs, with input from the FDA, and will be part of the post-marketing safety evaluation recommended by FDA for device manufacturers due to signal of harm associated with these devices.

K24HL150321 (Yeh, Robert)
NIH/National Heart, Lung, and Blood Institute
Using Claims-Based Signatures of Frailty to Support Individualized Treatment of Aortic Valve Stenosis and Coronary Artery Disease

01/01/2020 – 12/31/2024
Role: Principal Investigator

Study seeks to create signatures of frailty among older individuals based on administrative-claims records of healthcare interactions, and examine their association with outcomes among patients undergoing aortic valve replacement and percutaneous coronary intervention. We will examine whether these frailty signatures can be used to identify heterogeneous treatment effects of cardiac interventions within clinical trials. Mid-career mentorship grant to support junior faculty K-funded and post-doctoral mentees.

(Yeh, Robert)
Medtronic
Days at Home after Transcatheter or Surgical Aortic Valve Replacement in High and Intermediate-Risk Patients
The study seeks to compare days alive and not spent in the hospital in high- and intermediate-risk patients after TAVR and SAVR in the randomized treatment arms of the U.S. CoreValve High Risk and SURTAVI Clinical Trials linked with Medicare administrative claims data. Patient characteristics that predict days at home after TAVR and SAVR will be identified.

5/2020 – 12/2021
Role: Principal Investigator

(Yeh, Robert)
Medtronic
Evaluating the Impact of Different Site Monitoring Strategies in the US CoreValve Studies
Randomized trial that compares the influence of complete vs. limited site monitoring strategies on the frequency and cumulative incidence of adverse events in patients undergoing transcatheter aortic valve replacement in the US CoreValve studies.

5/2020 – 12/2021
Role: Principal Investigator

Report of Local Teaching and Training

Teaching of Students in Courses

2002 – 2003	Patient-Doctor II Student Preceptor 2 nd year medical students	Harvard Medical School 2-hr session per wk for 16 weeks
2005 – 2006	Patient-Doctor II Clinical Preceptor 2 nd year medical students	Harvard Medical School 2-hr session per wk for 16 weeks

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs):

2006 – 2009	Intern Teaching Day Medical Interns	University of California, San Francisco 2 2 hour lectures each year
2009 – 2015	Resident Report	Massachusetts General Hospital

	2 nd and 3 rd year medical residents	1 hour lecture as requested
2010 – 2015	Coronary Care Unit Resident Lecture Internal Medicine Residents	Massachusetts General Hospital 1 1 hour lecture per month
2011 – 2015	General Cardiology Fellow Didactic Series Cardiology Fellows	Massachusetts General Hospital 2 1 hour lectures per year
2011 – 2015	Interventional Cardiology Fellow Clinical Case Review Conference	Massachusetts General Hospital 1 1 hour session weekly
2015 –	Interventional Cardiology Fellow Clinical Case Review Conference	Beth Israel Deaconess Medical Center 1 1.5 hour session weekly
2015 –	General Cardiology Fellow Didactic Series Case Review Conference	Beth Israel Deaconess Medical Center 4 1 hours sessions per year
2017 – 2020	Statistical Education Series	Smith Center for Outcomes Research 1 1 hour lecture per year
2017 –	Epidemiology 208: Critique of the Literature	Harvard School of Public Health 1 3 hr seminar per year

Clinical Supervisory and Training Responsibilities

2010 – 2015	Clinical and Technical Training Interventional Cardiology Fellows	Massachusetts General Hospital 1.5 days per week
2011 – 2015	Clinical Supervision Coronary Intensive Care Unit	Massachusetts General Hospital 2 weeks per year
2010 – 2015	Clinical Supervision Cardiology Fellow Outpatient Clinic	Massachusetts General Hospital 4 afternoons per year
2011 – 2013	Clinical Supervision Cardiology Consult Service	Massachusetts General Hospital 2 weeks per year
2010 -	Clinical and Technical Training Interventional Cardiology Fellows	Beth Israel Deaconess Medical Center 1.5 days per week

Formally Supervised Trainees (research)

*Denotes current actively supervised mentees

2011 - 2014	Suzanne Baron, MD. Interventional Cardiology Fellow, Massachusetts General Hospital. Research support and mentorship resulted in Masters of Science in Clinical Epidemiology at Harvard School of Public Health. Current position: Assistant Professor of Medicine, University of Missouri – Kansas City.	
2011 - 2014	Beau Hawkins, MD. Interventional Cardiology Fellow, Massachusetts General Hospital. Research support and mentorship resulted in multiple original publications. Won the Herman Gold Young Investigator Award for mentored work, MGH Current position: Assistant Professor of Medicine, University of Oklahoma	
2011 – 2012	Jay Giri, MD. Vascular Interventional Fellow, Massachusetts General Hospital. Research mentorship resulted in multiple original publications. Current position: Associate Professor of Medicine, Perelman School of Medicine, University of Pennsylvania.	

- 2011 – 2015 Neil Wimmer, MD. Cardiology Fellow, Brigham and Women's Hospital
Research support and mentorship resulted in multiple original publications and Masters of Science in Clinical Epidemiology at Harvard School of Public Health.
Current position: Interventional Cardiology, Christiana Care, Delaware
- 2011 – 2018 Jason Wasfy, MD. Cardiology Fellow/Junior Faculty, Massachusetts General Hospital
Research support and mentorship contributed to multiple publications, including in *Circulation* and *Annals of Internal Medicine*. Won the 2016 American Heart Association Quality of Care and Outcomes Research Young Investigator Award for a mentored project. Harvard Catalyst KL2 awardee.
Current position: Assistant Professor of Medicine, Director of Outcomes Research, Massachusetts General Hospital, Harvard Medical School
- 2012 – *Jordan Strom, MD. Resident, Massachusetts General Hospital/Fellow, Beth Israel Deaconess Medical Center. Research support and mentorship contributed to funding through T32 training program, mentored research grant from the Center for Healthcare Delivery Science, and multiple original research publications, including in *Circulation*. I serve(d) as primary mentor on AHA Career Development Award and NHLBI-funded K23 career development award.
Current position: Assistant Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
- 2013 – 2015 Stephen Waldo, MD. Interventional Cardiology Fellow, MGH
Won the Herman Gold Young Investigator Award two consecutive years for mentored research, MGH, research support and mentorship contributed to multiple original publications, including in *Circulation* and the *Journal of the American College of Cardiology*.
Current Position: Assistant Professor of Medicine, University of Colorado
- 2013 – 2015 Jeffrey Bruckel, MD. Research and Quality Fellow, MGH
Mentorship contributed to several original research publications, funding via NIH Loan Repayment Program.
Current Position: Assistant Professor of Medicine, University of Rochester.
- 2014 – 2017 Michael Young, MD. Interventional Cardiology Fellow, MGH. Mentorship contributed to multiple first-authored peer reviewed research publications.
Current Position: Assistant Professor of Medicine, Dartmouth Hitchcock Medical Center.
- 2014 – *Eric Secemsky, MD. Interventional Cardiology Fellow, MGH. Mentorship contributed to multiple research manuscripts, including in *Annals of Internal Medicine*, *JAMA Cardiology*, and *JACC Cardiovascular Interventions*. Winner of the Jay D. Coffman Early Career Investigator Award from the American Heart Association for mentored research. Serving as primary mentor for NHLBI-supported K23 award.
Current Position: Assistant Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School.
- 2014 – *Enrico Ferro. Harvard Medical Student
Research mentorship contributed to American Heart Association Pre-Doctoral Fellowship Award, and multiple co-authored peer-reviewed publications.
Current position: Medical Resident, Brigham and Women's Hospital
- 2014 – 2018 Daniel Blumenthal MD, MBA. Cardiology Fellow, MGH. Mentorship contributed to multiple original research publications, and institutional research grant.
Current position: Instructor in Medicine, Massachusetts General Hospital, Harvard Medical School
- 2015 – *Neel Butala, MD. Medical Resident/Cardiology Fellow, MGH.
Mentorship contributed to multiple peer-reviewed publications and finalist for ACC Young Investigator Award competition. Primary mentor for LaDue mentored research grant.

Current position: Interventional cardiology fellow, MGH

- 2016 – 2020 Kamil Faridi, MD. Cardiology Fellow, BIDMC. Primary mentor for NIH NRSA F32 grant, mentorship contributed to multiple first-authored publications, including in *Circulation*.
Current position: Instructor in Medicine, Yale-New Haven Medical Center
- 2016 – 2019 Hector Tamez, MD. Interventional Cardiology Fellow, BIDMC. I was Dr. Tamez's primary mentor for his T32 research award.
Current position: Instructor in Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School.
- 2016 – 2017 Stephanie Ko, MD. MPH candidate, Harvard T.H. Chan School of Public Health. Primary mentor for Harvard School of Public Health MPH degree research practicum.
- 2016 – *Rishi Wadhwa, MD. Cardiology Fellow, Brigham and Women's Hospital. I served as primary mentor for ACC Merck Award, and for NHLBI-funded K23 career development Award.
Current position: Assistant Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School.
- 2017 – 2019 Harun Kundi, MD. Visiting International Research Fellow. Primary mentor for Master of Medical Sciences in Clinical Investigation program, Harvard Medical School. Mentorship contributed to multiple first-authored publications including in *European Heart Journal* and *JAMA Cardiology*.
- 2017 – *Mabel Chung, MD. Research Fellow, BIDMC. I serve as primary mentor on Harvard Combined Anesthesia T32 award.
Current position: Assistant Professor of Anesthesia, Massachusetts General Hospital, Harvard Medical School.
- 2018 – 2020 Colin O'Brien, MD. Medical resident, BIDMC. Mentorship on research resulting in oral presentation at the American College of Cardiology Scientific Sessions 2019, and co-authored paper published in JACC.
- 2019 – 2020 Nino Mihatov, MD. Cardiology Fellow, Massachusetts General Hospital.
Current position: Interventional Cardiology Fellow, Columbia New York Presbyterian Hospital
- 2019 – 2020 Emefah Loccoh. Sarnoff Fellow, 3rd year medical student, Ohio State Medical School. Was named finalist for Society of General Medicine Young Investigator competition 2020.
- 2019 – 2020 Aishwarya Raja. Sarnoff Fellow, 3rd year medical student, Mt Sinai Medical School.
- 2020 – Zaid Almarzooq. Cardiology Fellow, Brigham and Women's Hospital.

Formal Teaching of Peers (e.g. CME and other continuing education course):

No presentations below were sponsored by outside entities, unless otherwise indicated.

- 2014, 2015 "Cardiac Catheterization: Access, Stents, Antiplatelet Therapy and More"
MGH Update in Clinical Cardiology Course
- 2017 Why Should You Learn CTO PCI? Complex Coronary Intervention course. (sponsored by Boston Scientific, I was the creator of the content)
- 2020 Dual Antiplatelet Therapy in Complex Patients. (sponsored by Medtronic, I was the creator of the content)

Local Invited Presentations

No presentations below were sponsored by outside entities

- | | |
|------------|---|
| 2010, 2011 | “Acute Myocardial Infarction in Critical Care”
Critical Care Lecture Series, Massachusetts General Hospital |
| 2011 | “Prediction Modeling in Comparative Effectiveness Research: The DES Example”
Harvard Clinical Research Institute Scientific Meeting (Inaugural Lecture) |
| 2012 | “Comparative Effectiveness Research Methods”
MGH Heart Center Research Lecture, Massachusetts General Hospital |
| 2013 | “Instrumental Variables and Comparative Effectiveness Research”
Harvard Clinical Research Institute Scientific Meeting |
| 2013 | “Coronary Revascularization in the Era of Public Accountability: Opportunities for Value.”
Massachusetts General Hospital Cardiology Grand Rounds. |
| 2014 | “Extended Duration Dual Antiplatelet Therapy and Mortality”
Harvard Clinical Research Institute Scientific Meeting |
| 2015 | “Coronary Revascularization in the Era of Public Accountability.”
MGH Department of Medicine Grand Rounds |
| 2015 | “Coronary Revascularization in the Era of Public Accountability.”
Beth Israel Deaconess Medical Center Cardiology Grand Rounds. |
| 2015 | “Invasive management of coronary artery disease”. MGH Resident teaching conference. |
| 2016 | “The Smith Center for Outcomes Research In Cardiology: Transforming Cardiovascular Care Through Innovative Ideas and Analysis.” Cardiology Grand Rounds, Beth Israel Deaconess Medical Center |
| 2016 | “DAPT in 2016: How We Got Here, Where We’re Going.” Cardiology Grand Rounds, Beth Israel Deaconess Medical Center |
| 2017 | “Coronary Revascularization in the Era of Public Accountability.” Department of Medicine Grand Rounds. Beth Israel Deaconess Medical Center |
| 2017 | “The Uneasy Relationship Between Health Policy and Cardiovascular Care.” Cardiology Grand Rounds. Beth Israel Deaconess Medical Center |

Report of Regional, National, and International Invited Teaching and PresentationsRegional

No presentations below were sponsored by outside entities

- | | |
|------|--|
| 2012 | Visiting Professor, Cardiology Section. Veteran’s Administration Boston Healthcare System. Personalizing treatment choices to improve value in percutaneous coronary intervention. Boston, May 2012. |
| 2014 | Advances in the Management of Chronic Total Occlusions. Wentworth Douglass Hospital, Maine. |

- 2016 Chronic Total Occlusion Intervention. South Coast Hospital, Fall River, MA.
- 2017 Revascularization in the Era of Public Accountability. Julius Litter, MD Memorial Medical Grand Rounds Lecture. MetroWest Medical Center, Framingham.
- 2018 "DAPT in 2018: How We Got Here, Where We're Going." Medicine Grand Rounds, Carney Hospital, Dorchester, MA.
- 2018 "Examining the Relationship Between Health Policy and Cardiovascular Care Through the Lens of Data." Department of Epidemiology Seminar Series. Harvard TH Chan School of Public Health.
- 2018 "The Uneasy Relationship Between Health Policy and Cardiovascular Care." Cardiology Grand Rounds, Massachusetts General Hospital
- 2019 When Policy and Patient-Centered Care Diverge: Stories of Unintended Consequences. Lahey Hospital and Medical Center Cardiology Grand Rounds, Burlington, MA, January 2019.
- 2019 "Health Policy and Cardiovascular Care: Stories of Unintended Consequences." Department of Medicine Grand Rounds. Brigham and Women's Faulkner Hospital.
- 2020 "Precision, Pragmatism and Parachutes: Modernizing Empiricism in Cardiovascular Care." Cardiovascular Division Grand Rounds. Brigham and Women's Hospital.

National

* Denotes presentations sponsored by outside entities.

- 2010 Methods for the evaluation of comparative effectiveness: the example of drug-eluting and bare metal stents. Oral Abstract. American College of Cardiology Scientific Sessions, Atlanta.
- 2010 30-day all-cause readmission after percutaneous coronary intervention in Massachusetts: clinical predictors and hospital-variation of a new quality metric. Oral Abstract. American Heart Association Scientific Sessions,
- 2011 Accounting for bias in observational studies: Do DES really save lives? Invited faculty presentation at the American College of Cardiology Scientific Session.
- 2012 Propensity scores and instrumental variables. Invited faculty presentation at the American College of Cardiology Scientific Session.
- 2012 Successful examples from the National Cardiovascular Data Registry. Invited faculty presentation at the American College of Cardiology Scientific Session.
- 2012 When should a device or medication be stopped in clinical practice. Chair, scientific session at the American College of Cardiology Scientific Session.
- 2012 Comparative effectiveness research as the basis for defining appropriate use criteria in peripheral vascular disease. Invited Lecture, Society for Cardiovascular Angiography and Interventions Scientific Session, Las Vegas.
- 2012 Justifying an objective performance criterion for drug-eluting stent approval. Invited Lecture, FDA Town Hall Session, Transcatheter Cardiovascular Therapeutics Conference, Miami.
- 2012 What to do and what not do to starting in a university practice. Invited Lecture, Transcatheter Cardiovascular Therapeutics Conference, Miami.

- 2012 Challenges and opportunities in evaluation of medical device clinical trials. Invited Lecture, AdvaMed 2012: Medical Technology Conference. Boston.
- 2012 Management of Patients with CAD: Outcomes and Quality. Co-chair and Invited Lecture, American Heart Association Scientific Sessions, Los Angeles. Presentation titled: "Cardiovascular Outcomes Research in 2012: Identifying Targets for Quality Improvement, Challenging Existing Practice Paradigms, and Beyond."
- 2013 Getting access to data. Co-Chair and discussant, American College of Cardiology Scientific Sessions, San Francisco.
- 2013 Don't discriminate against the non-proximal LAD lesion. Invited Lecture, American College of Cardiology Scientific Session, San Francisco. Session titled "Appropriate use criteria for PCI: Influence on clinical practice today and tomorrow."
- 2013 Drug-eluting stents. Original abstract session Co-Chair. American College of Cardiology Scientific Session, San Francisco.
- 2013 Can experts see eye to eye – interpreting the cardiology literature. Session Co-Chair. American College of Cardiology Scientific Session, San Francisco.
- 2013 Interventional Cardiology in the Crosshairs: Promoting National Trust through Quality. Invited Lecture and Co-Chair. Society for Cardiovascular Angiography and Interventions Scientific Session. Orlando.
- 2013 If I could do it over again: learning from failed PCI. Session Co-Chair. American College of Cardiology Scientific Session, San Francisco.
- 2013 Live Case Discussant, How to Treat Coronary Theatre. Transcatheter Cardiovascular Therapeutics Conference, San Francisco.
- 2013 What to do and what not do to starting in a university practice. Invited Lecture, Transcatheter Cardiovascular Therapeutics Conference, San Francisco.
- 2013 Didactic Training for Clinical Epidemiologists and Outcomes Researchers. Invited Lecture, American Heart Association Scientific Sessions, Dallas.
- 2014 PCI in the Era of Public Accountability. Cardiology Grand Rounds. Perelman School of Medicine, University of Pennsylvania, March 2014.
- 2014 Evaluation and Management of STEMI and Shock. Invited Lecture, American College of Cardiology Scientific Sessions, Washington D.C.
- 2014 Getting access to data. Co-chair and discussant. American College of Cardiology Scientific Sessions, Washington D.C.
- 2014 Outcomes Research 2.0 – Big Data and Mobile Health. Session Chair. American Heart Association Quality of Care and Outcomes Research Conference, Baltimore.
- 2014 Knights of the Round Table: Is Door-To-Balloon Time No Longer a Useful Metric? Transcatheter Cardiovascular Therapeutics Conference, Washington D.C..
- 2014 Transradial Intervention in ACS: What are the benefits and why?" Invited Lecture, Transcatheter Cardiovascular Therapeutics Conference, Washington D.C.
- 2014 Cardiac Cath Lab Complications. Session Creator and Moderator. Transcatheter Cardiovascular Therapeutics Conference, Washington D.C.

- 2014 Improving PCI Quality of Care. America Heart Association Scientific Sessions, Chicago.
- 2014 Early Career for the Interventional Cardiologist. America Heart Association Scientific Sessions, Chicago. November 2014.
- 2014 Primary PCI State of the Art: Radial or Not. Invited Lecture, American Heart Association Scientific Sessions, Dallas.
- 2015 Rapid update of recent CTO literature. Invited Lecture, American College of Cardiology Scientific Sessions, San Diego.
- 2015 Is Door-To-Balloon Time A Useful Metric? Invited Lecture, American College of Cardiology Scientific Sessions, San Diego.
- 2015 Dual Antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents For Treatment of Acute Coronary Syndrome: Analysis from the Dual Antiplatelet Therapy Study. Plenary/Oral Abstract. American College of Cardiology Scientific Sessions, San Diego.
- 2015 DAPT in Acute Coronary Syndromes. Invited Lecture, American College of Cardiology Scientific Sessions, San Diego.
- 2015 Dual antiplatelet therapy after STEMI. Invited Lecture, Cardiovascular Research Foundation Fellows Course, Miami.
- 2015 The Evidence Supporting Transradial PCI. Invited Lecture, Cardiovascular Research Foundation Fellows Course, Miami.
- 2015 *The Hybrid Approach to Chronic Total Occlusion PCI. Invited Lecture, Interventional Cardiology Training Course. Course sponsored by Abbott Vascular, content was created without input of the sponsor. University of Washington, Seattle.
- 2015 Updated Guidelines and Clinical Data for Complex Higher Risk Procedures. Invited Lecture, Complex and Higher-Risk Indicated Patients (CHIP) Course, Cardiovascular Research Foundation, Seattle.
- 2015 Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)! Invited Lecture, Transcatheter Cardiovascular Therapeutics Conference, San Francisco.
- 2015 Assessment and Implications of Surgical Inoperability: Who Is at High Risk? Invited Lecture, Transcatheter Cardiovascular Therapeutics Conference, San Francisco.
- 2015 High-Risk Intervention: Risk for the Operators or the Patient? Reconciling Risk Scores, Appropriateness, Public Reporting, and Institutional Needs. Invited Lecture, Transcatheter Cardiovascular Therapeutics Conference, San Francisco.
- 2015 Individualizing Treatment Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Analysis of the DAPT Study. Late-Breaking Clinical Trial Plenary Presentation, American Heart Association Scientific Sessions, Orlando.
- 2015 Door-to-Balloon Time: Time to Move On. Invited lecture, American Heart Association Scientific Sessions, Orlando.
- 2015 Young Investigator Award Abstract Presentations, Quality of Care and Outcomes Research. Session moderator. American Heart Association Scientific Sessions, Orlando.
- 2016 PCI in the Era of Public Accountability. Cardiology Grand Rounds. Emory University School of Medicine, Atlanta.

- 2016 What is the DAPT Score? Invited Lecture, CRT Conference. Washington, D.C.
- 2016 Performing and Evaluating the Angiogram. Invited Lecture, CTO Summit. New York.
- 2016 DAPT Duration: Here for the Long Haul. Invited Lecture, American Heart Association Quality of Care and Outcomes Research Conference, Phoenix.
- 2016 Comparative Effectiveness Research of Drug and Devices: Is It Leading or Misleading Us? Session Chair. American Heart Association .Quality of Care and Outcomes Research Conference, Phoenix.
- 2016 High-Risk PCI in an Era of Public Reporting: Risks and Benefits. Invited Lecture, American College of Cardiology Scientific Sessions, Chicago.
- 2016 Should Current USA and European DAPT Guidelines Be Changed? Yes! Longer Is Better. Invited Debate, American College of Cardiology Scientific Sessions, Chicago.
- 2016 Interventional Challenging Cases: Coronary – Endovascular. Session Chair, American College of Cardiology Scientific Sessions, Chicago.
- 2016 Longer DAPT Wins, Less MI and ST (DAPT Trial). Invited Lecture, American College of Cardiology Scientific Sessions, Chicago.
- 2016 PCI in the Era of Public Accountability. Invited Lecture, Cardiology Grand Rounds. University of Pittsburgh Medical Center, Pittsburgh, PA
- 2016 Transradial Access and Intervention: A Step-by-Step Approach. Invited Lecture, Cardiovascular Research Foundation Fellows Course, Orlando.
- 2016 Acute Coronary Syndrome: ST-elevation Myocardial Infarction Case Presentation. Cardiovascular Research Foundation Fellows Course, Orlando.
- 2016 Effect of Public Reporting and Insurance Qualifications on the Management of High Risk Patients. Invited Lecture, Society for Cardiovascular Angiography and Interventions Scientific Session, Orlando.
- 2016 Complex PCI Case-Based Clinical Decision Making. Session chair. Society for Cardiovascular Angiography and Interventions Scientific Session, Orlando.
- 2016 Chronic Total Occlusion Case Presentation. Invited presentation. Society for Cardiovascular Angiography and Interventions Scientific Session, Orlando.
- 2016 Coronary Revascularization in the Era of Public Accountability. Invited Lecture, Cardiovascular Grand Rounds. Christiana Care Health System, Wilmington, DE.
- 2016 Individualizing Care: Which Patients Might Benefit from Prolonged DAPT? Who Might Be Harmed. Invited presentation. Transcatheter Cardiovascular Therapeutics, Washington, D.C.
- 2016 Public Reporting, Appropriateness Criteria, and the CHIP Initiative: At Odds or Working Together. Invited presentation. Transcatheter Cardiovascular Therapeutics, Washington, D.C.
- 2016 Limitations of Observational Studies and Randomized Trials. Session Moderator. Transcatheter Cardiovascular Therapeutics, Washington, D.C.
- 2016 Coronary Revascularization in the Era of Public Accountability. Cardiology Grand Rounds. University Hospitals Health System, Case Western Reserve University.

- 2016 Patients Do Better While Their Cardiologists are at AHA? Embedding Negative Controls in Observational Studies. Invited Lecture. American Heart Association Scientific Sessions. New Orleans.
- 2016 What Is High Risk PCI: Beyond Anatomical Considerations. Invited Lecture. American Heart Association Scientific Sessions. New Orleans.
- 2016 Public Reporting of PCI Mortality Outcomes - Truth and Misconception. Invited Lecture. American Heart Association Scientific Sessions. New Orleans.
- 2016 Public Reporting, Physician Behavior and Patient Outcomes. Invited Presentation. New York State Department of Health, Cardiac Advisory Committee.
- 2016 Visiting Professor, Cleveland Clinical Heart and Vascular Institute. Cardiac Grand Rounds: Coronary Revascularization in the Era of Public Accountability. Cardiac Noon Conference: DAPT in 2016: How We Got Here, Where We're Going. Cleveland, OH.
- 2017 The Uneasy Relationship Between Health Policy and Cardiovascular Care. Cardiology Grand Rounds. University of California, San Francisco.
- 2017 DAPT in 2017: How We Got Here, Where Are We Going. Cardiac Service Line Grand Rounds. Kaiser Permanente San Francisco.
- 2017 PCI of High Risk Patients Under Hemodynamic Support. American College of Cardiology Symposium, Washington DC.
- 2017 Contemporary External Challenges to Coronary Revascularization. Invited Lecture, American College Cardiology Scientific Sessions, Washington DC.
- 2017 Mechanical and Hemodynamic Support in High Risks Subsets: Impella and Tandem Heart. Invited Lecture, American College Cardiology Scientific Sessions, Washington DC.
- 2017 Overuse, Underuse or Just Right? Fundamental Debates in High Risk PCI in 2017. Session Chair. American College Cardiology Scientific Sessions, Washington DC.
- 2017 The Best Coronary and Peripheral Interventional Challenging Cases. Session Chair. American College Cardiology Scientific Sessions, Washington DC.
- 2017 The Uneasy Relationship Between Health Policy and Cardiovascular Care. Cardiology Grand Rounds. University of Utah.
- 2017 Who Should Undergo CTO PCI? Invited Lecture, CardioVascular Innovations Conference, Denver.
- 2017 Revascularization in Cardiogenic Shock: Is It Important? Invited Lecture, Complex and Higher-Risk Indicated Patients (CHIP) Course, Cardiovascular Research Foundation, Seattle.
- 2017 DAPT Duration with Contemporary DES: Prolonged DAPT for Most ACS Patients. Invited Lecture. Transcatheter Cardiovascular Therapeutics Conference. Denver.
- 2017 Nature's Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization. Invited Lecture. Transcatheter Cardiovascular Therapeutics Conference. Denver.
- 2017 Do Patients Really Do Better When Their Cardiologists Are Away at Conferences? Embedding Controls in Observational Studies. Invited Lecture. Transcatheter Cardiovascular Therapeutics Conference. Denver.

- 2017 Crossing Challenging Anatomy: Device Selection to Efficiently Complete Complex Procedures. Invited Lecture. Transcatheter Cardiovascular Therapeutics Conference. Denver.
- 2017 How I Use Social Media. Invited Lecture. Transcatheter Cardiovascular Therapeutics Conference. Denver.
- 2017 Best Interventional Trials of 2017. Invited Lecture. American Heart Association Scientific Sessions. Los Angeles.
- 2017 Is Mortality the Ultimate Performance Measure? Invited Lecture. American Heart Association Scientific Sessions. Los Angeles.
- 2017 The First Five Years: Considerations for a Physician Scientist Pathway. Invited Lecture. American Heart Association Scientific Sessions. Los Angeles.
- 2017 STEMI vs. NSTEMI vs. Stable CAD - Post-PCI Optimal DAPT Duration: Scoring the Complexity of Stenting and Disease. Invited Lecture. New York Cardiovascular Symposium, New York, Dec 2017.
- 2017 Wires and Guides. Invited Lecture. Society for Coronary Angiography and Interventions Fellows Course, Las Vegas, Dec 2017.
- 2017 Optimal Duration of DAPT. Invited Lecture. Society for Coronary Angiography and Interventions Fellows Course, Las Vegas, Dec 2017.
- 2017 CTO Techniques: Learning, Mastering and Knowing When to Say When. Invited Lecture. Society for Coronary Angiography and Interventions Fellows Course, Las Vegas, Dec 2017.
- 2018 Live Case Discussant: CTO PCI. CTO Summit 2018, New York. Jan 2018.
- 2018 What to do if..... Session moderator. CTO Summit 2018, New York. Jan 2018.
- 2018 Managing hematoma and loss of visualization. Invited Lecture. CTO Summit 2018 Conference, New York. Jan 2018.
- 2018 Antegrade and Retrograde CTO PCI. Panel member. CRT Conference. Washington DC, 2018.
- 2018 Reach for the STAR, Meet the Experts: CTO. Invited Lecture. CRT Conference. Washington DC, March 2018.
- 2018 Scores to Guide DAPT Duration: DAPT Score, Paris, Precise DAPT. Invited Lecture. CRT Conference. Washington DC, March 2018.
- 2018 DAPT Duration for ACS Patients. Invited Lecture. American College of Cardiology Scientific Sessions, Orlando, March 2018.
- 2018 Patient Selection for CTO PCI. Invited Lecture. American College of Cardiology Scientific Sessions, Orlando, March 2018.
- 2018 Salvaging a CTO Disaster. Invited Lecture. Scottsdale Interventional Forum. Scottsdale, AZ, March 2018.
- 2018 What is the Optimal Duration of DAPT. Invited Lecture. Scottsdale Interventional Forum. Scottsdale, AZ, March 2018.
- 2018 Unresolved Issues in Coronary Artery Disease Management. Panelist. Scottsdale Interventional Forum. Scottsdale, AZ, March 2018.

- 2018 The Uneasy Relationship Between Health Policy and Cardiovascular Care. Heart and Vascular Center Grand Rounds, Dartmouth Hitchcock Medical Center. Lebanon, MA, September 2018.
- 2018 A Complex Case of Bleeding and Ischemia. Transcatheter Cardiovascular Therapeutics Conference. San Diego.
- 2018 Approach to High Bleeding Risk Patients: Reduce DAPT Duration. Transcatheter Cardiovascular Therapeutics Conference. San Diego, September 2018.
- 2018 No Role for Observational Studies in Effectiveness Comparison: The Staged vs. Culprit Only PCI for STEMI Case Study. Transcatheter Cardiovascular Therapeutics Conference. San Diego, September 2018.
- 2018 Closure Devices versus Manual Pressure for Standard Sheaths. Transcatheter Cardiovascular Therapeutics Conference. San Diego, September 2018.
- 2019 Assessing Risk and Benefit Based on the CTO Operator Skill Set: Which case to attempt, when to stop. CTO Summit. New York, March 2019.
- 2019 Live Case Presentations: Complex Coronary Intervention: American College of Cardiology, New Orleans, 2019.
- 2019 The EXTEND Study: Linking Medtronic CoreValve Data to CMS Claims. Symposium on the Methodology of Linking TTR with the CMS Claims Database for Long-Term Device Surveillance. United States Food and Drug Administration, Silver Springs, MD, April, 2019.
- 2019 Health Policy and Cardiovascular Care: Stories of Unintended Consequences. Cardiology Grand Rounds. University of Connecticut, Hartford Hospital, Hartford, CT, April 2019.
- 2019 Duke Cardiology Fellowship Visiting Professor, Cardiology Grand Rounds Lecture – Health Policy and Cardiovascular Care: Stories of Unintended Consequences. Duke University Medical Center. Durham, NC, May 2019.
- 2019 Public Reporting is a Health Policy Failure. Society for Cardiovascular Angiography and Interventions National Scientific Meeting. Las Vegas, May 2019.
- 2019 Stent Selection in High Bleeding Risk Patients: Does It Matter. Society for Cardiovascular Angiography and Interventions National Scientific Meeting. Las Vegas, May 2019.
- 2019 Retrograde CTO PCI: Making the Connection. Society for Cardiovascular Angiography and Interventions National Scientific Meeting. Las Vegas, May 2019.
- 2019 Antegrade Dissection Reentry Techniques. Society for Cardiovascular Angiography and Interventions National Scientific Meeting. Las Vegas, May 2019.
- 2019 Peripheral Drug-Coated Devices and Mortality in a National Claims Database. US Food and Drug Administration Advisory Panel on Drug-Coated Devices for Peripheral Arterial Revascularization. Gaithersburg, MD, June 20, 2019.
- 2019 How to Manage Coronary Perforations. CHIP Seattle Complex Intervention Course. Seattle, WA, August 2019.
- 2019 Optimizing Antiplatelet Therapy After DES. Transcatheter Cardiovascular Therapeutics Conference, San Francisco, September 2019.
- 2019 Left Main PCI: The Default is Prolonged Dual Antiplatelet Therapy. Transcatheter Cardiovascular Therapeutics Conference, San Francisco, September 2019.

- 2019 We Should Not Do Procedures Just Because We Can. Transcatheter Cardiovascular Therapeutics Conference, San Francisco, September 2019.
- 2019 The Challenge of Equipoise and Generalizability in Trials. Transcatheter Cardiovascular Therapeutics Conference, San Francisco September 2019.
- 2019 Historical Perspective on Public Reporting of Cardiovascular Outcomes. American Heart Association Scientific Sessions, Philadelphia, November 2019.
- 2019 The DAPT Score Should Be Used to Guide Antiplatelet Duration After PCI. American Heart Association Scientific Sessions, Philadelphia, November 2019.
- 2020 Live Case Discussant: Complex CTO PCI. CTO Summit, New York, February 2020.
- 2020 Session Moderator: State of the Evidence for CTO. CTO Summit, New York, February 2020.
- 2020 Modern Approach to Antegrade Dissection Reentry for CTO PCI. CRT Meeting, Washington, D.C., February 2020.
- 2020 Antiplatelet Monotherapy After PCI: Drop the P2Y12 Inhibitor. CRT Meeting, Washington, D.C., February 2020.
- 2020 Is Short DAPT After DES: A Class Effect For All Second Generation DES? CRT Meeting, Washington, D.C., February 2020.
- 2020 Who is the Real High Bleeding Risk Patient? Are Scores Reliable? CRT Meeting, Washington, D.C., February 2020.
- 2020 Introduction to Instrumental Variable Analysis for Comparative Efficacy and Safety Evaluation. Led workshop for U.S. Food and Drug Administration Center for Devices and Radiologic Health (CDRH) Cardiovascular Division, and Office of Clinical Evidence and Analysis. February 2020.
- 2020 Management of the Complex PCI Patient. (Session Moderator). High Bleeding Risk Patients Undergoing PCI: How I assess and Treat to Optimize Outcomes (Speaker). Society for Cardiovascular Angiography and Interventions 2020 (Virtual).
- 2020 The Scientific and Strategic Value of Real World Evidence. Keynote speaker, Boston Scientific, Inc. Evidence Generation Summit. Aug 2020.
- 2020 The Value of Combining Real World Data with Randomization: The EXTEND Study. Presentation to U.S. Food and Drug Administration Center for Devices and Radiologic Health (CDRH) Cardiovascular Division, and Office of Clinical Evidence and Analysis. August 2020.

International

No presentations below were sponsored by outside entities

- 2012 - 2015 Confounders in observational studies: using the method of propensity score." International Collaborative and Distance Learning Course in Clinical Research. October 2012-2015.
- 2015 Dual Antiplatelet Therapy. Invited Presentation. Toronto Heart Summit. June 2015.
- 2016 Balancing the risks of ischemia and bleeding: Lessons from the DAPT Study. Invited Lecture. Canadian Cardiovascular Society Annual Meeting, Montreal. October 2016.

- 2020 Recent impactful Late-reaking clinical trials: Highlights and Clinical Implications. Invited Panelist. CIT2020 (Chinese interventional cardiology conference). Beijing (virtual), China. June 2020.
- 2020 Short DAPT Strategy in the Contemporary PCI Era: Routine of Selective. Invited Lecture. TCT Asia Pacific Conference. Seoul (virtual), Korea. July 2020.
- 2020 Complex High-Risk Lesions or High Bleeding Risk Patients. Panel Discussant. TCT Asia Pacific Confernece. Seoul (virtual), Korea. July 2020.

Report of Clinical Activities and Innovations

Current Certification and Licensure

Licensure

- 2005 Massachusetts Medical License
2006 California Medical License

Certification

- 2006 American Board of Internal Medicine, Internal Medicine, 8/21/2006.
2009 American Board of Internal Medicine, Cardiovascular Diseases, 11/4/2009.
2010 American Board of Internal Medicine, Interventional Cardiology, 11/1/2010.

Practice Activities

2003 – 2006	Ambulatory and Hospital Care	Internal Medicine, MGH	5 days/60 hours/week
2006 – 2008	Ambulatory and Hospital Care	Cardiology UC San Francisco	5 days/60 hours/week
2009 – 2015	Hospital Care	Interventional Cardiology Cardiac Catheterization Laboratory, MGH	1.5 Sessions per week
2010 – 2015	Hospital Care	Cardiology consultation and inpatient management	20 hours/week, 1 of every 11 weeks
2011 – 2015	Hospital Care	Coronary Critical Care Attending Physician	2-4 weeks per year
2015 –	Hospital Care	Interventional Cardiology Cardiac Catheterization Laboratory, BIDMC	1-2 days per week

Clinical Innovations

Transradial catheterization (2010 – 2013).

Part of group to develop transradial catheterization techniques and local expertise within the MGH cardiac catheterization laboratory ~2010 onward. This technique is associated with fewer bleeding complications and improved patient experience compared to traditional transfemoral catheterization in selected populations. Perform > 80% of catheterizations, including interventions for ST-elevation myocardial infarction, via the transradial approach. It is now standard of care

PrOE personalized risk assessment and informed consent tool (2011-2015)

Applied a novel information technology infrastructure during the informed consent process that produces individualized risk-predictions for complications in patients scheduled to undergo PCI, working closely with the MGH Physician's Organization. Developed and validated risk models that are currently utilized in the Vascular and Cardiac implementations of PrOE.

Hospital Quality Benchmarking and Personalized Risk Prediction

- Created risk-adjustment model to identify the individual patient benefit of drug-eluting stents. This model was been implemented at over 20 cath labs nationwide (including the Mayo Clinic, Mid America Heart Institute, and Kaiser Permanente San Francisco) as part of the e-PRISM (Health Outcomes Sciences, Inc) personalized informed consent tool (2011-2014)
- Created risk-adjustment models for in-hospital death and stroke after carotid endarterectomy and carotid artery stenting. **These models were implemented in more than 130 cardiac cath labs nationwide as part of the National Cardiovascular Data Registry's CARE registry between 2012-2017, and supported hospital quality benchmarking for participating hospitals.**
- Created 30-day readmission model after PCI, known to be implemented at Washington Medstar Hospital, among other institutions. (2013-2017)
- Created individualized risk-prediction instrument to define optimal antiplatelet treatment strategy (DAPT Score), and built web-based tool to support clinicians. **Partnered with the American College of Cardiology to produce a phone-based app, now used in more than 100 countries and referenced in societal antiplatelet guidelines.** (2014-2016)

Chronic Total Occlusion/Complex Coronary Intervention

Co-Director, MGH Chronic Total Occlusion Revascularization (CTO) Program. (2012 - 2015)

- Co-led program to bring novel anterograde and retrograde techniques to improve success in revascularization of chronically occluded coronary arteries.
- Performed the first retrograde PCI procedure in the Metro-Boston area (with Farouc Jaffer)
- Performed first antegrade dissection reentry PCI in the Metro-Boston area (with Farouc Jaffer).
- Co-developed highest volume CTO PCI referral program in the New England.'

Director, BIDMC Chronic Total Occlusion (CTO) Revascularization Program. (2015 -)

- Established the Chronic Total Occlusion PCI Program at BIDMC.
- Established dedicated CTO PCI fellowship training program, trained Dr. Hector Tamez-Aguilar. Dr. Tamez subsequently hired on to staff to serve as Co-Director of Program at BIDMC
- Performed complex coronary demonstration "Live Case" procedures, including those broadcasted to the American College of Cardiology Scientific Sessions plenary session.
- Have proctored CTO PCI at a large number of medical centers regionally, including Tufts Medical Center, St. Francis Hospital in Hartford, Baystate Medical Center, University of Massachusetts, Charlton Memorial Hospital, Catholic Memorial Hospital and Maine Medical Center.

Patient-Reported Outcomes Program, MGH Cardiac Catheterization Laboratory. (2013 - 2015).

- Implemented standard assessment of patient health status, including angina, dyspnea, quality of life, and mental health using a tablet-based program that is fully integrated with the electronic medical record system.
- Programs enables automated assessment of angina and health status in patients with coronary artery disease.

Patient-Reported Outcomes Program, BIDMC Cardiac Catheterization Laboratory. (2016 - 2019).

- Implemented standard assessment of patient health status, including angina, dyspnea, quality of life, and mental health using a tablet-based program.
- Supported by Innovation Grant from the Center for Healthcare Delivery Science

Report of Education of Patients and Service to the Community

No activities were sponsored by outside entities.

Educational Material for Patients and the Lay Community

2011 - "10 Things Your Cardiologist Wants You To Know." Contributed to article in Chicago Tribune by Danielle Braff. http://articles.chicagotribune.com/2012-02-09/health/sc-health-0208-senior-health-cardiologist-20120208_1_heart-disease-heart-problems-healthy-heart

2013 - "The Risks of Shoveling Snow." Interview in Boston Magazine, article by Melissa Malamut.

<http://blogs.bostonmagazine.com/hub-health/2013/01/16/snow-shoveling-pain/>

2020 – “A Closer Look at Your Coronary Arteries.” Contributed to article in the *Harvard Heart Letter* by Julie Corliss.

2020 – “Major Boston hospital finds dramatic drop in stroke, heart attack, and cancer patients during coronavirus pandemic.” Contributed to article in Boston Globe by Lyz Kowalczyk, article based on our original research study.

Report of Scholarship

Peer-Reviewed Publications in Print or Other Media

* designates formally supervised mentee.

Research Investigations:

1. **Yeh RW**, Ponce de Leon A, Agasino CB, Hahn JA, Daley CL, Hopewell PC, Small PM. Stability of Mycobacterium tuberculosis DNA genotypes. *Journal of Infectious Diseases*. 1998 Apr; 177(4):1107-11. PMID: 9354994.
2. **Yeh RW**, Hopewell PC, Daley CL. Simultaneous infection with two strains of MTB identified by restriction fragment length polymorphism analysis. *International Journal for TB and Lung Disease*. 1999 June; 3(6):537-9. PMID: 10383069.
3. Gregory SA, Ferencik M, Achenbach SA, **Yeh RW**, Hoffman U, Inglessis I, Cury RC, Nieman K, McNulty IA, Laffan JA, Pomerantsev EV, Brady TJ, Semigran MJ, Jang, IK. Comparison of sixty-four-slice multidetector computed tomographic coronary angiography to coronary angiography with intravascular ultrasound for the detection of transplant vasculopathy. *American Journal of Cardiology*. 2006 Oct 1;98(7):871-76. PMID: 16996866.
4. Foo SY, Everett BM, **Yeh RW**, Criss D, Laposata M, Van Cott EM, Jang IK. Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. *American Heart Journal*. 2006 Aug;152(2):290.e1-7. PMID: 16875910.
5. **Yeh RW**, Everett BM, Foo SY, Van Cott EM, Laposata M, Jang IK. Predictors for the development of elevated titers of heparin/platelet factor 4 antibodies in patients undergoing cardiac catheterization. *American Journal of Cardiology*. 2006 Aug 1;98(3):419-21. PMID: 16860036.
6. Everett BM, **Yeh RW**, Foo SY, Criss D, Van Cott EM, Laposata M, Avery EG, Hoffman WD, Walker J, Torchiana D, Jang IK. The prevalence of heparin/platelet factor 4 antibody before and after cardiac surgery. *Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Annals of Thoracic Surgery*. 2007 Feb;83(2):592-7.
7. Ferencik M, Gregory SA, Butler J, Achenbach S, **Yeh RW**, Hoffman U, Inglessis I, Cury RC, Nieman K, McNulty IA, Healy JA, Brady TJ, Semigran MJ, Jang IK. Analysis of cardiac dimensions, mass and function in heart transplant recipients using 64-slice multi-detector computed tomography. *Journal of Heart and Lung Transplantation*. 2007 May; 26(5):478-84. PMID: 17449417.
8. Cruz-Gonzalez I, Sanchez-Ledesma M, Baron S, Healy JF, Watanabe H, Osakebe M, **Yeh RW**, Jang IK. Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. *Journal of Thrombosis and Thrombolysis*. 2008 Apr; 25(2):214-8. PMID: 17632689,
9. **Yeh RW**, Wiviott SW, Giugliano RP, Morrow DA, Shui A, Buros J, Bradner JE, Jang IK, Gibson CM, Antman EM. Thrombocytopenia is associated with adverse outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes: a TIMI 11B substudy. *American Journal of Cardiology*. 2007 Dec 15;100(12):1734-8. PMID: 18082517.

10. Baron SJ, **Yeh RW**, Cruz-Gonzalez I, Healy JL, Pomerantsev E, Garasic J, Drachman D, Rosenfield K, Jang IK. Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease. *Catheterization and Cardiovascular Interventions*. 2008 Jul 1;72(1):116-20. PMID: 1854627
11. Cruz-Gonzalez I, Sanchez-Ledesma M, Baron S, Healy JL, **Yeh RW**, Jang IK. What is the optimal anticoagulation level with argatroban during coronary intervention? *Blood Coagulation & Fibrinolysis*. 2008 Jul;19(5):401-4. PMID: 18600089.
12. **Yeh RW**, Baron S, Healy JF, Pomerantsev E, McNulty IA, Cruz-Gonzalez I, Jang IK. Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes. *Catheterization and Cardiovascular Intervention*. 2009 Aug 1;74(2):359-64. PMID: 19213062.
13. Yoon JH, **Yeh RW**, Nam KH, Joffman WD, Agnihotri AK, Jang IK. Safety and efficacy of argatroban therapy during the early post-cardiac surgery period. *Journal of Thrombosis and Thrombolysis*. 2010 Oct;30(3):276-80. PMID: 20449633.
14. **Yeh RW**, Sidney S, Sorel M, Chandra M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. *New England Journal of Medicine*. 2010 June 10;362:233-44. PMID: 20558366.
 - 500+ citations.
 - Primary figure used in the joint American College of Cardiology/American Heart Association 2013 Guidelines on the management of ST-elevation Myocardial Infarction.
 - Published as lead article in *New England Journal of Medicine*, with accompanying editorial: Brown JR, O'Connor GT. Coronary heart disease and prevention in the United States. *N Engl J Med* 2010; 362:2150-2153.
15. Longmore RB, **Yeh RW**, Kennedy KF, Anderson HV, White CJ, Longmore LS, Rosenfield K, Ho KK, Spertus JA. Clinical referral patterns for carotid artery stenting versus carotid endarterectomy: results from the Carotid Artery Revascularization and Endarterectomy Registry. *Circulation: Cardiovascular Interventions*. 2011 Feb 1;4(1):88-94. PMID: 21224465.
16. **Yeh RW**, Kennedy K, Spertus JA, Parikh SA, Sakhujia R, Anderson HV, White CJ, Rosenfield KA. Do post-marketing surveillance studies represent "real world" populations? A comparison of patient characteristics and outcomes after carotid artery stenting. *Circulation*. 2011 Apr 5;123(13):1384-90. PMID: 21422383.
17. **Yeh RW**, Chandra M, McCulloch CE, Go AS. Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study. *BMC Medicine*. 2011 Jun 24;9(1):78. PMID: 21702899.
18. Defaria Yeh, D, Lease Lonergan K, Fu D, Yeh RW, Echt DS, Foster E. Clinical factors and echocardiographic techniques related to the presence, size, and location of acoustic windows for leadless cardiac pacing. *Europace*. 2011 Dec;13(12):1760-5. PMID: 21798878.
19. McNulty EJ, Ng W, Spertus JA, Zaroff JG, **Yeh RW**, Ren XM, Lundstrom RJ. Surgical candidacy and selection biases in non-emergent left main stenting: implications for observational studies. *J Am Coll Cardiol Intv*. 2011 Sep;4(9):1020-1027. PMID: 21939943.
20. **Yeh RW**, Normand ST, Wolf RE, Jones PG, Ho KK, Cohen DJ, Cutlip DE, Mauri L, Kugelmass AD, Amin A, Spertus JA. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention. *Circulation*. 2011 Oct 4;124(14):1557-64. PMID: 21900079.
21. **Yeh RW**, Normand ST, Wang Y, Barr CD, Dominici F. Geographical disparities in the incidence and outcomes of hospitalized myocardial infarction: Does a Rising Tide Lift All Boats? *Circulation*:

Cardiovascular Quality and Outcomes. 2012 Mar 1;5(2):197-204. PMID: 22354937.

22. **Yeh RW**, Rosenfield K, Zelevinsky K, Mauri L, Sakhuja R, Shivapour DM, Lovett A, Weiner BH, Jacobs AK, Normand ST. Sources of hospital variation in short term readmission rates after percutaneous coronary intervention. *Circulation: Cardiovascular Interventions*. 2012 Apr 1;5(2):227-36. PMID: 22438431.
23. Armstrong EJ, Xing L, Zhang J, Zheng Y, Shunk KA, **Yeh RW**, Farzaneh-Far R, Yu B, Jang IK. Association between leukocyte telomere length and drug-eluting stent strut coverage by optical coherence tomography. *Journal of the American College of Cardiology*. 2012 Jun 12;59(24):2218-9. PMID: 22676944.
24. Kato K, Yonetsu T, Kim SJ, Xing L, Lee H, McNulty I, **Yeh RW**, Sakhuja R, Zhang S, Uemura S, Yu B, Mizuno K, Jang IK. Non-culprit plaques in patients with acute coronary syndromes (ACS) have more vulnerable features compared to those with non-ACS: a 3-vessel optical coherence tomography study. *Circulation: Cardiovascular Imaging*. 2012 Jul 1;5(4):433-40. PMID: 22679059.
25. Yonetsu T, Kim JS, Kato K, Kim SJ, Xing L, **Yeh RW**, Sakhuja R, McNulty I, Lee H, Zhang S, Uemura S, Yu B, Kakuta T, Jang IK. Comparison of incidence and time course of neoatherosclerosis between bare metal and drug-eluting stents using optical coherence tomography. *American Journal of Cardiology*. 2012 Oct 1;110(7):933-9. PMID: 22727183
26. Rothman RD, Baggish AL, O'Callaghan C, Lowry PA, Bhatt AB, Macrae CA, Yannekis G, Sanborn DM, Mela T, **Yeh RW**, Palacios I, Vlahakes GJ, Fifer MA. Management strategy in 249 consecutive patients with obstructive hypertrophic cardiomyopathy referred to a dedicated program. *American Journal of Cardiology*. 2012 Oct 15;110(8):1169-74. PMID: 22777536.
27. Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy DF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand ST, Rumsfeld J, Messenger JC, **Yeh RW**. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. *Archives of Internal Medicine*. 2012 Aug 13;172(15):1145-52. PMID: 22777536.
 - Published with accompanying editorial: Groeneveld PW. How drug-eluting stents illustrate our health system's flawed relationship with technology. *Arch Intern Med*. 2012;172(15):1152-1153.
28. Hawkins BM*, Kennedy KF, Giri J, Saltzman AJ, Rosenfield K, Drachman DE, White CJ, Spertus JA, **Yeh RW**. Pre-procedural risk quantification for carotid stenting using the CAS score: a report from the NCDR CARE Registry. *Journal of the American College of Cardiology*. October 2012;60:1617-22. PMID: 22999733.
 - Risk-adjustment model currently used by the National Cardiovascular Data Registry's Peripheral Vascular Intervention Registry for hospital benchmarking for carotid stenting (over 150 sites).
29. Wimmer NJ*, **Yeh RW**, Cutlip DE, Mauri L. Risk prediction for adverse events following carotid stenting for higher surgical risk patients. *Stroke*. 2012 Dec;43(12):3218-24. PMID: 23127975
 - Risk-adjustment model currently used by the National Cardiovascular Data Registry's Peripheral Vascular Intervention Registry for hospital benchmarking for carotid endarterectomy (over 150 sites).
30. Kato K, Yonetsu T, Kim SJ, Xing L, Lee H, McNulty I, **Yeh RW**, Sakhuja R, Zhang S, Uemura S, Yu B, Mizuno K, Jang IK. Comparison of non-culprit coronary plaque characteristics between patients with and without diabetes: a 3-vessel optical coherence tomography study. *JACC: Cardiovascular Interventions*. 2012 Nov;5(11):1150-8. PMID: 23174639.
31. Zigler CM, Watts K, **Yeh RW**, Wang Y, Coull B, Dominici F. Model feedback in Bayesian propensity score estimation. *Biometrics*. 2013 Mar;69(1):263-73. PMID: 23379793.

32. Wayangankar SA, Abu-Fadel MS, Aronow HD, Kennedy KF, Gupta R, **Yeh RW**, Gray WA, Rosenfield K, and Hennebry TA. Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting: a propensity score analysis from the NCDR. *Circulation: Cardiovascular Interventions*. 2013 Apr;6(2):131-8. PMID: 23379793.
33. Amin AP, Bachuwar A, Reid KJ, Chhatriwalla AK, Salisbury AC, **Yeh RW**, Kosiborod M, Wang TY, Alexander KP, Cohen DJ, Spertus JA, Bach RG. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. *Journal of the American College of Cardiology*. 2013 May 28;61(21):2130-8. PMID: 23541975
34. Rhee EP, Clish CB, Ghorbani A, Larson MG, Elmariah S, McCabe E, Yang Q, Cheng S, Pierce K, Deik A, Souza AL, Farrell L, Domos C, **Yeh RW**, Palacios I, Rosenfield K, Vasan RS, Florez JC, Wang TJ, Fox CS, Gerszten RE. A Combined Epidemiologic and Metabolomic Approach Improves CKD Prediction. *J Am Soc Nephrol*. 2013 Jul;24(8):1330-8. PMID: 23687356
35. Wimmer NJ*, Resnic FS, Mauri L, Matheny ME, Piemonte TC, Pomerantsev E, Ho KKL, Robbins SL, Waldman HM, **Yeh RW**. Risk-treatment paradox in the selection of transradial access for percutaneous coronary intervention. *Journal of the American Heart Association*. 2013 May 24;2(3)e000174. PMID: 23709565.
36. Wasfy JH*, Rosenfield K, Zelevinsky K, Sakhuja R, Lovett A, Spertus JA, Wimmer NJ, Mauri L, Normand SL, **Yeh RW**. A Prediction Model to Identify Patients at High Risk for 30-Day Readmission After Percutaneous Coronary Intervention. *Circulation: Cardiovascular Quality and Outcomes*. 2013 Jul 1;6(4):429-35. PMID 23819957.
37. Giri J*, **Yeh RW**, Kennedy KF, Hawkins BM, Weinberg I, Weinberg MD, Parikh SA, Garasic J, Jaff MR, White CJ, Rosenfield K. Unprotected Carotid Artery Stenting in Modern Practice. *Catheterization and Cardiovascular Interventions*. 2014 Mar 1;83(4):595-602. PMID: 23804411.
38. Yonetsu T, Kato K, Uemura S, Kim BK, Jang Y, Kang SJ, Park SJ, Lee s, Kim SJ, Jia H, Vergallo R, Abtahian F, Tian J, Hu S, **Yeh RW**, Sakhuja R, McNulty I, McNulty I, Lee H, Zhang S, Yu B, Kakuta T, Jang IK. Features of coronary plaque in patients with metabolic syndrome and diabetes mellitus assessed by 3-vessel optical coherence tomography. *Circulation: Cardiovascular Imaging*. 2013 Sep;6(5):665-73. PMID 23922003.
39. Wimmer NJ*, Resnic FS, Mauri L, Matheny ME, **Yeh RW**. Comparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of “falsification hypotheses” in observational studies of comparative effectiveness. *Journal of the American College of Cardiology*. 2013 Dec 3;62(22):2147-8. PMID 23954334
40. Vardi M, Novack V, Pencina MJ, Doros G, Burke DA, Elmariah S, Cutlip DE, Mauri L, **Yeh RW**. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: A meta-analysis and critical examination of current methodologies. *Catheter Cardiovasc Interv*. 2014 May 1;83(6):975-83. PMID: 23996913
41. Masoudi FA, Ponirakis A, **Yeh RW**, Maddox TM, Beachy J, Casale PN, Curtis JP, De Lemos J, Fonarow G, Heidenreich P, Koutras C, Kremers M, Messenger J, Moussa I, Oetgen WJ, Roe MT, Rosenfield K, Shields TS, SPertus JA, Wei J, White C, Young CH, Rumsfeld JS. Cardiovascular Care Facts: A Report from the National Cardiovascular Data Registry – 2011. *Journal of the American College of Cardiology*. 2013, Nov 19;62(21)1931-47. PMID: 24036027
42. **Yeh RW**, Vasaiwala S, Forman DE, Silbaugh TS, Zelevinski Z, Lovett A, Normand ST, Mauri L. Instrumental variable analysis to compare effectiveness of stents in the extremely elderly. *Circulation: Cardiovascular Quality and Outcomes*. 2014 Jan;7(1):118-24. PMID: 24254887.

43. Chiang A, Gada H, Kodali SK, Lee MS, Jeremias A, Pinto DS, Bangalore S, **Yeh RW**, Henry TD, Lopez-Cruz G, Mehran R, Kirtane AJ. Procedural variation in the performance of primary percutaneous coronary intervention for ST-elevation myocardial infarction: a SCAI-based survey study of US interventional cardiologists. *Catheter Cardiovasc Interv*. 2014 Apr 1;83(5):721-6. PMID 24273213.
44. Kalim S, Clish CB, Wenger J, Elmariah S, **Yeh RW**, Deferio JJ, Piernce K, Deik A, Gerszten RE, Thadano R, Rhee EP. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. *J Am Heart Assoc*. 2013 Dec 5;2(6):e000542. doi: 10.1161/JAHA.113.000542. PMID: 24308938
45. Matteau A, **Yeh RW**, Kereiakes D, Orav EJ, Massaro J, Steg PG, Normand SL, Cutlip DE, Mauri L. Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy Study). *Am J Cardiol*. 2014 Apr 1;113(7):1146-52. PMID 24332248.
46. McCabe JM, Kennedy KF, Eisenhauer AC, Waldman HM, Mort EA, Pomerantsev E, Resnic FS, **Yeh RW**. Reporting trends and outcomes in ST-elevation myocardial infarction national hospital quality assessment programs. *Circulation*. 2014 Jan 14;129(2):194-202. PMID: 24249721.
47. Hawkins BM*, McCoy LA, Neely M, Adusumalli S, Messenger JC, Drachman DE, Bass TA, O'Gara PT, Rao SV, **Yeh RW**. Impact of academic year timing on percutaneous coronary intervention outcomes at training institutions. *Journal of the American College of Cardiology*. 2014 Mar 18;63(10):1025-6. PMID 2433492.
48. Stefanescu A, Macklin EA, Lin E, Dudzinski DM, Johnson J, Kennedy KF, Jacoby D, Defaria Yeh D, Lewis GD, **Yeh RW**, Liberthson R, Lui G, Bhatt AB. Usefulness of the Seattle Heart Failure Model to Identify Adults With Congenital Heart Disease at High Risk of Poor Outcome. *Am J Cardiol*. 2014 Mar 1;113(5):865-70. PMID 24411285.
49. Wasfy JH*, Strom JB*, O'Brien C, Zai AH, Luttrell J, Kennedy KF, Spertus JA, Zelevinsky K, Normand SL, Mauri L, **Yeh RW**. Causes of Short-Term Readmission After Percutaneous Coronary Intervention. *Circ Cardiovasc Interv*. 2014 Feb;7(1):97-103. PMID: 24425587
50. Giri J*, Kennedy KF, Weinberg I, Hawkins BM, Calfon Press M, Drachman D, McCormick DJ, Aronow HD, White CJ, Rosenfield K, **Yeh RW**. Comparative Effectiveness of Commonly Used Devices for Carotid Artery Stenting: An NCDR (National Cardiovascular Data Registry) Analysis. *J Am Coll Cardiol Intv*. 2014 Feb;7(2):171-7. PMID 24440025.
51. McNulty EJ, Hung YY, Almers LM, Go AS, **Yeh RW**. Population trends from 2000-2011 in nuclear myocardial perfusion imaging use. *JAMA*. 2014 Mar 26;311(12):1248-1249. PMID 24668108.
52. Wimmer NJ*, Spertus JA, Kennedy, KF, Anderso HV, Curtis JP, Weintraub WS, Singh M, Rumsfeld JS, Masoudi FA, **Yeh RW**. A clinical prediction model suitable for assessing hospital quality for patients undergoing carotid endarterectomy. *Journal of the American Heart Association*. 2014 Jun 17;3(3). PMID 24938712.
53. Strom JB*, Wimmer NJ*, Wasfy JH*, Kennedy K, **Yeh RW**. Association between operator procedure volume and patient outcomes in percutaneous coronary intervention: a systematic review and meta-analysis. *Circulation: Cardiovascular Quality and Outcomes Research*. 2014 Jul;7(4):560-6. PMID 24939939.
54. Wimmer NJ*, Cohen DJ, Wasfy JH, Rathore SS, Mauri L, **Yeh RW**. Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: might some

- delays be acceptable? *American Heart Journal*. 2014 Jul;168(1):103-9. PMID: 24952866.
55. McCabe JM, Kennedy KF, **Yeh RW**. Defining unavoidable delays in primary percutaneous coronary intervention: discordance among patients excluded from national cardiovascular quality registries. *Journal of the American Heart Association*. 2014 Jun 24;3(3). PMID: 24965027.
56. Vardi M, Perez J, Griffin PJ, Burke DA, **Yeh RW**, Cutlip DE. Usefulness of Postmarket Studies to Evaluate Long-Term Safety of Coronary Eluting Stents (from the ENDEAVOR and PROTECT Programs). *Am J Cardiol*. 2014 Aug 15;114(4):528-33. PMID: 24994546.
57. Wasfy JH*, Strom JB*, Waldo SW*, O'Brien C, Wimmer NJ, Zai AH, Luttrell J, Spertus JA, Kennedy KF, Normand SL, Mauri L, **Yeh RW**. Clinical preventability of 30-day readmission after percutaneous coronary intervention. *J Am Heart Assoc*. 2014 Sep 26;3(5). pii: e001290. doi: 10.1161/JAHA.114.001290. PMID: 25261531
58. Waldo SW*, Secemski EA*, O'Brien C, Kennedy KF, Pomerantsev E, Sundt TM, McNulty EJ, Scirica BM, **Yeh RW**. Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention. *Circulation*. 2014 Dec 23;130(25):2295-301. PMID 25391519.
- Published with accompanying editorial: Garratt KN. Challenges and importance of finding hidden confounders when conducting comparative effectiveness studies using registry data: the impact of surgical turn-down on percutaneous coronary intervention mortality.
59. **Yeh RW**, Czarny MJ*, Normand ST, Kereiakes D, Holmes D, Brindis R, Weaver WD, Rumsfeld J, Roe M, Kim S, Driscoll-Shempp P, Mauri L. Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial: Comparing Hospitals and Patients in the Dual Antiplatelet Therapy Study versus the National Cardiovascular Data Registry. *Circulation: Cardiovasc Qual Outcomes*. 2015 Jan;8(1):96-102. PMID 25399847
60. Elmariah S, Mauri L, Doros G, Galper BZ, O'Neill KE, Steg PG, Kereiakes DJ, **Yeh RW**. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. *Lancet*. 2015 Feb 28;385(9970):792-8. PMID 25467565.
- Published simultaneously with the presentation of the Dual Antiplatelet Therapy (DAPT) Study at the American Heart Association Scientific Sessions, 2014.
 - Accompanying editorial: Lemesle G. Dual antiplatelet therapy and non-cardiovascular mortality. *Lancet*. 2014.
61. Kumar A, Matheny ME, Ho KK, **Yeh RW**, Piemonte TC, Waldman H, Shah PB, Cope R, Normand ST, Donnelly S, Robbins S, Resnic FS. The Data Extraction and Longitudinal Trend Analysis Network Study of Distributed Automated Postmarket Cardiovascular Device Safety Surveillance. *Circ Cardiovasc Qual Outcomes*. 2015 Jan;8(1):38-46. PMID: 25491915.
62. Mauri, L, Kereiakes DJ, **Yeh RW**, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand ST, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Lee PV, Rinaldi MJ, Massaro JM, on behalf of the Dual Antiplatelet Therapy (DAPT) Study Investigators. Twelve or 30 Months of Dual Antiplatelet Therapy After Drug-eluting Stents. *New England Journal of Medicine*. 2014 Dec 4;371(23):2155-66. PMID: 25399658.
63. **Yeh RW**, Mauri L, Wolf RE, Romm IK, Lovett A, Shahian D, Normand ST. Population Trends in Rates and Outcomes of Coronary Revascularization. *JAMA Internal Medicine*. 2015 Mar 1;175(3):454-6. PMID: 25559059.
64. Garg P, Galper BZ, Cohen DJ, **Yeh RW**, Mauri L. Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. *Am Heart J*. 2015 Feb;169(2):222-233.e5. PMID: 25641531.

65. Waldo SW*, McCabe JM, O'Brien C, Kennedy KF, Joynt KE, **Yeh RW**. Association between public reporting of outcomes with procedural management and mortality for patients with acute myocardial infarction. *Journal of the American College of Cardiology*. 2015 Mar 24;65(11):1119-26. PMID: 25790884.
66. Kereiakes DJ, **Yeh RW**, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H., Meredith IT, Ormiston J, Tanguay FJ, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the Dual Antiplatelet Therapy randomized clinical trial. *JAMA*. 2015 Mar 17;313(11):1113-21. PMID:25781440.
67. **Yeh RW**, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MH, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. *Journal of the American College of Cardiology*. 2015 May 26;65(20):2211-21. PMID: 25787199.
 - Presented as a Featured Clinical Research Presentation at the American College of Cardiology Scientific Sessions, 2015.
 - Published simultaneously with presentation in the *Journal of the American College of Cardiology*
68. Giri J*, Parikh SA, Kennedy KF, Weinberg I, Donaldson C, Hawkins BM, McCormick DJ, Jackson B, Armstrong EJ, Ramchand P, White CJ, Jaff MR, Rosenfield K, **Yeh RW**. Proximal versus distal embolic protection for carotid artery stenting: a national cardiovascular data registry analysis. *JACC Cardiovasc Interv*. 2015 Apr 20;8(4):609-15. PMID: 25907088.
69. Hawkins BM*, Kennedy KF, Aronow HD, Nguyen LL, White CJ, Rosenfield K, Normand SL, Spertus JA, **Yeh RW**. Hospital variation in carotid stenting outcomes. *JACC Cardiovasc Interv*. 2015 May;8(6):858-63. PMID: 25999111.
70. Secemsky EA*, Matteau A, **Yeh RW**, Steg PG, Camenzind E, Wijns W, McFadden E, Mauri L; PROTECT Trial Investigators. Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials). *Am J Cardiol*. 2015 Jun 15;115(12):1678-84. PMID: 25910523.
71. Chatterjee S, Herrmann HC, Wilensky RL, Hirshfeld J, McCormick D, Frankel DS, **Yeh RW**, Armstrong EJ, Kumbhani DJ, Giri J. Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device: A Systematic Review of Published Reports and Analytic Review of the FDA MAUDE Database. *JAMA Intern Med*. 2015 Jul;175(7):1104-9. PMID: 25938303.
72. Wang ZJ, Zhou YJ, Galper BZ, Gao F, **Yeh RW**, Mauri L. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. *Heart*. 2015 Oct;101(20):1631-8. PMID: 26025084.
73. Christopoulos G, Karpaliotis D, Alaswad K, **Yeh RW**, Jaffer FA, Wyman RM, Lombardi WL, Menon RV, Grantham JA, Kandzari DE, Lembo N, Moses JW, Kirtane AJ, Parikh M, Green P, Finn M, Garcia S, Doing A, Patel M, Bahadorani J, Tarar MN, Christakopoulos GE, Thompson CA, Banerjee S, Brilakis ES. Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry. *Int J Cardiol*. 2015 Jun 27;198:222-228. PMID: 26189193.
74. Matteau A, **Yeh RW**, Camenzind E, Steg PG, Wijns W, Mills J, Gershlick A, de Belder M, Ducrocq G, Mauri L. Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. *Am J Cardiol*. 2015 Sep 1;116(5):686-93. PMID: 26187674.
75. Tabtabai S, DeFaria Yeh D, Stefanescu A, Kennedy K, **Yeh RW**, Bhatt AB. National Trends in

- Hospitalizations for Patients With Single-Ventricle Anatomy. *Am J Cardiol*. 2015 Sep 1;116(5):773-8. PMID: 26100589.
76. Christopoulos G, Wyman RM, Alaswad K, Karpaliotis D, Lombardi W, Grantham JA, **Yeh RW**, Jaffer FA, CIPHER DJ, Rangan BV, Christakopoulos GE, Kypreos MA, Lembo N, Kandzari D, Garcia S, Thompson CA, Banerjee S, Brilakis ES. Clinical Utility of the Japan-Chronic Total Occlusion Score in Coronary Chronic Total Occlusion Interventions: Results from a Multicenter Registry. *Circ Cardiovasc Interv*. 2015 Jul;8(7):e002171. PMID: 2616285.
 77. Wasfy JH*, Singal G, O'Brien C, Blumenthal DM, Kennedy KF, Strom JB, Spertus JA, Mauri L, Normand ST, **Yeh RW**. Enhancing the Prediction of 30-Day Readmission After Percutaneous Coronary Intervention Using Data Extracted by Querying of the Electronic Health Record. *Circ Cardiovasc Qual Outcomes*. 2015 Sep;8(5): 477-85. PMID: 26286871.
 78. Waldo SW*, Chang L, Strom JB, O'Brien C, Pomerantsev E, **Yeh RW**. Predicting the Presence of an Acute Coronary Lesion Among Patients Resuscitated From Cardiac Arrest. *Circ Cardiovasc Interv*. 2015 Oct;8(10). PMID: 2645368.
 79. Wasfy JH*, Hidrue MK, **Yeh RW**, Armstrong K, Dec GW, Pomerantsev EV, Fifer MA, Ferris TG. Differences Among Cardiologists in Rates of Positive Coronary Angiograms. *J Am Heart Assoc*. 2015 Oct 16;4(10). pii: e002393. PMID: 26475298.
 80. Bruckel JT*, Jaffer FA, O'Brien C, Stone L, Pomerantsev E, **Yeh RW**. Angina Severity, Depression, and Response to Percutaneous Revascularization in Patients With Chronic Total Occlusion of Coronary Arteries. *J Invasive Cardiol*. 2016 Feb;28(2):44-51. PMID: 2647704.
 81. Kereiakes DJ, **Yeh RW**, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; DAPT Study Investigators. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. *JACC Cardiovasc Interv*. 2015 Oct;8(12):1552-62. PMID: 26493248.
 82. Bruckel J*, Wagle N, O'Brien C, Elias J, McKenna S, Meyers P, Fifer MA, Pomerantsev E, **Yeh RW**. Feasibility of a Tablet Computer System to Collect Patient-reported Symptom Severity in Patients Undergoing Diagnostic Coronary Angiography. *Crit Pathw Cardiol*. 2015 Dec;14(4):139-45. PMID: 26569653.
 83. Mauri L, Elmariah S, **Yeh RW**, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D'Agostino RB Sr, Braunwald E, Kereiakes DJ; DAPT Study Investigators. Causes of late mortality with dual antiplatelet therapy after coronary stents. *Eur Heart J*. 2016 Jan 21;37(4):378-85. PMID: 26586780.
 84. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, **Yeh RW**, Turner MB. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. *Circulation*. 2016 Jan 26;133(4):e38-60. PMID: 26673558.
 85. Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, **Yeh RW**, Cohen DJ, Cutlip DE, Massaro JM, Hsieh WH, Mauri L; DAPT Study Investigators. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. *JACC Cardiovasc Interv*. 2016 Jan 25;9(2):138-47. PMID: 26793956.
 86. Waldo SW*, Abtahian F, Kennedy KF, Scirica BM, Mahmood S, **Yeh RW**. Incidence and predictors of incomplete revascularization in a contemporary cohort. *Coron Artery Dis*. 2016 May;27(3):191-8. PMID: 26882019.

87. Karacsonyi J, Karatasakis A, Karpalotis D, Alaswad K, **Yeh RW**, Jaffer FA, Wyman MR, Lombardi WL, Grantham JA, Kandzari DE, Lembo N, Moses JW, Kirtane AJ, Parikh MA, Green P, Finn M, Garcia S, Doing A, Patel M, Bahadorani J, Martinez Parachini JR, Resendes E, Rangan BV, Ungi I, Thompson CA, Banerjee S, Brilakis ES. Effect of Previous Failure on Subsequent Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention (from a Contemporary Multicenter Registry). *Am J Cardiol*. 2016 Apr 15;117(8):1267-71. PMID: 26899493.
88. Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, **Yeh RW**, Garratt KN, Lee DP, Steg PG, Weaver WD, Holmes DR Jr, Brindis RG, Trebacz J, Massaro JM, Hsieh WH, Mauri L; DAPT Study Investigators. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. *Circulation*. 2016 May 3;133(18):1772-82. PMID: 26994121.
89. Kereiakes DJ, **Yeh RW**, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, Mauri L; DAPT Study Investigators. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. *J Am Coll Cardiol*. 2016 May 31;67(21):2492-502. PMID: 27046159.
90. **Yeh RW**, Secemsky EA*, Kereiakes DJ, Normand ST, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. *JAMA*. 2016 Apr 26;315(16):1735-49. PMID: 27022822
 - Presented as a Late Breaking Clinical Trial at the American Heart Association Scientific Sessions, 2015.
 - Published in *JAMA* with accompanying editorial: Pencina MJ, Peterson ED. Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling *JAMA*. 2016;315(16):1713-1714
91. Wimmer NJ*, Secemsky EA*, Mauri L, Roe MT, Saha-Chaudhuri P, Dai D, McCabe JM, Resnic FS, Gurm HS, **Yeh RW**. Effectiveness of arterial closure devices for preventing complications with percutaneous coronary intervention: an instrumental variable analysis. *Circ Cardiovasc Interv*. 2016 Apr;9(4):e003464. PMID: 27059685
92. Karatasakis A, Tarar MN, Karpalotis D, Alaswad K, **Yeh RW**, Jaffer FA, Wyman RM, Lombardi WL, Grantham JA, Kandzari DE, Lembo NJ, Moses JW, Kirtane AJ, Parikh M, Garcia S, Doing A, Pershad A, Shah A, Patel M, Bahadorani J, Shoultz CA Jr, Danek BA, Thompson CA, Banerjee S, Brilakis ES. Guidewire and microcatheter utilization patterns during antegrade wire escalation in chronic total occlusion percutaneous coronary intervention: Insights from a contemporary multicenter registry. *Catheter Cardiovasc Interv*. 2016 May 17. PMID: 27184465
93. Karpalotis D, Karatasakis A, Alaswad K, Jaffer FA, **Yeh RW**, Wyman RM, Lombardi WL, Grantham JA, Kandzari DE, Lembo NJ, Doing A, Patel M, Bahadorani JN, Moses JW, Kirtane AJ, Parikh M, Ali ZA, Kalra S, Nguyen-Trong PK, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Thompson CA, Banerjee S, Brilakis ES. Outcomes With the Use of the Retrograde Approach for Coronary Chronic Total Occlusion Interventions in a Contemporary Multicenter US Registry. *Circ Cardiovasc Interv*. 2016 Jun;9(6). PMID: 27307562
94. Danek BA, Karatasakis A, Karpalotis D, Alaswad K, **Yeh RW**, Jaffer FA, Patel M, Bahadorani J, Lombardi WL, Wyman MR, Grantham JA, Doing A, Moses JW, Kirtane A, Parikh M, Ali ZA, Kalra S, Kandzari DE, Lembo N, Garcia S, Rangan BV, Thompson CA, Banerjee S, Brilakis ES. Use of antegrade dissection re-entry in coronary chronic total occlusion percutaneous coronary intervention in a contemporary multicenter registry. *Int J Cardiol*. 2016 Jul 1;214:428-37. PMID: 27088405
95. Chatterjee S, **Yeh RW**, Sardar P, Ul Hassan Virk H, Mukherjee D, Parikh SA, Kumbhani DJ, Kirtane A, Bashir R, Cohen H, Kolansky DM, Wilensky RL, Giri J. Is multivessel intervention in ST-elevation myocardial infarction associated with early harm? Insights from observational data. *Catheter Cardiovasc Interv*. 2016 Nov;88(5):697-707. PMID: 27341605

96. Christakopoulos GE, Karpaliotis D, Alaswad K, **Yeh RW**, Jaffer FA, Wyman RM, Lombardi W, Grantham JA, Kandzari DA, Lembo N, Moses JW, Kirtane A, Parikh M, Green P, Finn M, Garcia S, Doing A, Patel M, Bahadorani J, Christopoulos G, Karatasakis A, Thompson CA, Banerjee S, Brilakis ES. Contrast Utilization During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. *J Invasive Cardiol*. 2016 Jul;28(7):288-94. PMID: 27342206
97. Federspiel JJ, Anstrom KJ, Xian Y, McCoy LA, Effron MB, Faries DE, Zettler M, Mauri L, **Yeh RW**, Peterson ED, Wang TY. Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. Treatment With Adenosine Diphosphate Receptor Inhibitors—Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Investigators. *JAMA Cardiol*. 2016 Jul 20. Doi: 10.1001/jamacardio.2016.1783. [Epub ahead of print] PMID: 27438179
98. McCabe JM*, Waldo SW, Kennedy KF, **Yeh RW**. Treatment and Outcomes of Acute Myocardial Infarction Complicated by Shock After Policy Changes in New York State Public Reporting. *JAMA Cardiology*. 2016 Sep 1;1(6):648-54. PMID: 27463734
99. Danek BA, Karatasakis A, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel MP, Bahadorani J, Lombardi WL, Wyman RM, Grantham JA, Kandzari DE, Lembo NJ, Doing AH, Toma C, Moses JW, Kirtane AJ, Ali ZA, Parikh M, Garcia S, Nguyen-Trong PK, Karacsonyi J, Alame AJ, Kalsaria P, Thompson C, Banerjee S, Brilakis ES. Effect of Lesion Age on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary US Multicenter Registry. *Can J Cardiol*. 2016 Dec;32(12):1433-1439. PMID: 27476986
100. Decker C, Garavalia L, Garavalia B, Gialde E, **Yeh RW**, Spertus J, Chhatriwalla AK. Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention. *Am Heart J*. 2016 Aug;178:190-7. Doi: 10.1016/j.ahj.2016.03.027. PMID: 27502869
101. Stefanescu Schmidt AC, DeFaria Yeh D, Tabtabai S, Kennedy KF, **Yeh RW**, Bhatt AB. National Trends in Hospitalizations of Adults With Tetralogy of Fallot. *Am J Cardiol*. 2016 Sep 15;118(6):906-11. PMID: 27530825
102. Karacsonyi J, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Bahadorani J, Karatasakis A, Danek BA, Doing A, Grantham JA, Karpaliotis D, Moses JW, Kirtane A, Parikh M, Ali Z, Lombardi WL, Kandzari DE, Lembo N, Garcia S, Wyman MR, Alame A, Nguyen-Trong PK, Resendes E, Kalsaria P, Rangan BV, Ungi I, Thompson CA, Banerjee S, Brilakis ES. Use of Intravascular Imaging During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. *J Am Heart Assoc*. 2016 Aug 20;5(8). Pii: e003890. Doi: 10.1161/JAHA.116.003890. PMID: 27543800
103. Tanguturi VK, Temin E, **Yeh RW**, Thompson RW, Rao SK, Mallick A, Cavallo E, Ferris TG, Wasfy JH. Clinical Interventions to Reduce Preventable Hospital Readmission After Percutaneous Coronary Intervention. *Circ Cardiovasc Qual Outcomes*. 2016 Sep;9(5):600-4. PMID: 27553598.
104. Karacsonyi J, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Bahadorani J, Doing A, Ali ZA, Karatasakis A, Danek BA, Rangan BV, Alame AJ, Banerjee S, Brilakis ES. Prevalence, indications and management of balloon uncrossable chronic total occlusions: Insights from a contemporary multicenter US registry. *Catheter Cardiovasc Interv*. 2017 Jul;90(1):12-20. PMID: 27650935.
105. Ghoshhajra BB, Takx RA, Stone LL, Girard EE, Brilakis ES, Lombardi WL, **Yeh RW**, Jaffer FA. Real-time fusion of coronary CT angiography with x-ray fluoroscopy during chronic total occlusion PCI. *Eur Radiol*. 2017 Jun;27(6):2464-2473. PMID: 27663227.
106. Karatasakis A, Danek BA, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel MP, Bahadorani

- JN, Wyman RM, Lombardi WL, Grantham JA, Kandzari DE, Lembo NJ, Doing AH, Moses JW, Kirtane AJ, Garcia S, Parikh MA, Ali ZA, Karacsonyi J, Kalra S, Rangan BV, Kalsaria P, Thompson CA, Banerjee S, Brilakis ES. Impact of Proximal Cap Ambiguity on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Multicenter US Registry. *J Invasive Cardiol*. 2016 Oct;28(10):391-396. PMID: 27705889.
107. Resor CD, Nathan A, Kereiakes DJ, **Yeh RW**, Massaro JM, Cutlip DE, Steg PG, Hsieh WH, Mauri L. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. *Circulation*. 2016 Oct 4;134(14):989-998. PMID: 27576774.
108. Danek BA, Karatasakis A, Karpaliotis D, Alaswad K, **Yeh RW**, Jaffer FA, Patel MP, Mahmud E, Lombardi WL, Wyman MR, Grantham JA, Doing A, Kandzari DE, Lembo NJ, Garcia S, Toma C, Moses JW, Kirtane AJ, Parikh MA, Ali ZA, Karacsonyi J, Rangan BV, Thompson CA, Banerjee S, Brilakis ES. Development and Validation of a Scoring System for Predicting Periprocedural Complications During Percutaneous Coronary Interventions of Chronic Total Occlusions: The Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO) Complications Score. *J Am Heart Assoc*. 2016 Oct 11;5(10). pii: e004272. PMID: 27729332.
109. Martinez-Parachini JR, Karatasakis A, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Bahadorani J, Doing A, Nguyen-Trong PK, Danek BA, Karacsonyi J, Alame A, Rangan BV, Thompson CA, Banerjee S, Brilakis ES. Impact of diabetes mellitus on acute outcomes of percutaneous coronary intervention in chronic total occlusions: insights from a US multicentre registry. *Diabet Med*. 2017 Apr;34(4):558-562. PMID: 27743404.
110. Secemsky EA*, Butala NM, Kartoun U, Mahmood S, Wasfy JH, Kennedy KF, Shaw SY, **Yeh RW**. Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. *J Am Heart Assoc*. 2016 Oct 17;5(10). pii: e004310. PMID: 27792650.
111. Secemsky EA*, Kirtane A, Bangalore S, Jovin IS, Shah RM, Ferro EG, Wimmer NJ, Roe M, Dai D, Mauri L, **Yeh RW**. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients with ST-Segment Elevation Myocardial Infarction in the United States. *JACC Cardiovasc Interv*. 2016 Dec 12;9(23):2376-2386. PMID: 27838271.
112. Garcia S, Chadi Alraies M, Karatasakis A, Yannopoulos D, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel MP, Bahadorani J, Karacsonyi J, Kalsaria P, Danek B, Banerjee S, Brilakis ES. Coronary artery spatial distribution of chronic total occlusions: Insights from a large US registry. *Catheter Cardiovasc Interv*. 2017 Jul;90(1):23-30. PMID: 27860111.
113. Chatterjee S, Weinberg I, **Yeh RW**, Chakraborty A, Sardar P, Weinberg MD, Kabrhel C, Barnes GD, Mukherjee D, Kumbhani D, Bashir R, Vaidya A, Smith A, Fuchs B, Groeneveld P, Giri J. Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. *Thromb Haemost* 2017 Jan 26;117(2):246-251. PMID: 27882375.
114. Karatasakis A, Danek BA, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Bahadorani JN, Lombardi WL, Wyman RM, Grantham JA, Kandzari DE, Lembo NJ, Doing AH, Toma C, Moses JW, Kirtane AJ, Parikh MA, Ali ZA, Garcia S, Kalsaria P, Karacsonyi J, Alame AJ, Thompson CA, Banerjee S, Brilakis ES. Comparison of various scores for predicting success of chronic total occlusion percutaneous coronary intervention. *Int J Cardiol*. 2016 Dec 1;224:50-56. doi: 10.1016/j.ijcard.2016.08.317. PMID: 27611917.
115. Karatasakis A, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel MP, Bahadorani JN, Lombardi WL, Wyman RM, Grantham JA, Kandzari DE, Lembo NJ, Doing AH, Toma C, Moses JW, Kirtane AJ, Ali Z, Parikh M, Garcia S, Danek BA, Karacsonyi J, Alame A, Kalsaria P, Thompson C, Banerjee S, Brilakis ES. Approaches to percutaneous coronary intervention of right coronary artery chronic total occlusions: insights from a multicentre US registry. *EuroIntervention*. 2016 Dec 10;12(11):e1326-e1335. doi: 10.4244/EIJ-D-16-00265. PMID: 27934609.

116. Wasfy JH*, Zigler CM, Choirat C, Wang Y, Dominici F, **Yeh RW**. Readmission Rates After Passage of the Hospital Readmissions Reduction Program: A Pre-Post Analysis. *Ann Intern Med*. 2017 Mar 7;166(5):324-331. PMID: 28024302.
117. Blumenthal DM, Olenski AR, **Yeh RW**, DeFaria Yeh D, Sarma A, Stefanescu Schmidt AC, Wood MJ, Jena AB. Sex Differences in Faculty Rank Among Academic Cardiologists in the United States. *Circulation*. 2017 Feb 7;135(6):506-517. PMID: 28153987.
118. **Yeh RW**, Silber S, Chen L, Chen S, Hiremath S, Neumann FJ, Qiao S, Saito S, Xu B, Yang Y, Mauri L. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program. *JACC Cardiovasc Interv*. 2017 Feb 13;10(3):247-254. PMID: 28109872.
119. Bobb JF, Ho KK, **Yeh RW**, Harrington L, Zai A, Liao KP, Dominici F. Time-Course of Cause-Specific Hospital Admissions During Snowstorms: An Analysis of Electronic Medical Records From Major Hospitals in Boston, Massachusetts. *Am J Epidemiol*. 2017 Feb 15;185(4):283-294. doi: 10.1093/aje/kww219. PMID: 28137774.
120. Stefanescu Schmidt AC*, Kereiakes DJ, Cutlip DE, **Yeh RW**, D'Agostino RB Sr, Massaro JM, Hsieh WH, Mauri L; DAPT Investigators. Myocardial Infarction Risk after Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study. *Circulation*. 2017 May 2;135(18):1720-1732. PMID: 28228427.
121. Tamez H, Pinto DS, Kirtane AJ, Litherland C, **Yeh RW**, Dangas GD, Mehran R, Deliargyris EN, Ortiz G, Gibson CM, Stone GW. Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial. *JAMA Cardiol*. 2017 Jun 1;2(6):673-677. PMID: 28249084.
122. Waldo SW*, McCabe JM, Kennedy KF, Zigler CM, Pinto DS, **Yeh RW**. Quality of Care at Hospitals Identified as Outliers in Publicly Reported Mortality Statistics for Percutaneous Coronary Intervention. *Circulation*. 2017 May 16;135(20):1897-1907. PMID: 28249879.
123. Secemsky EA*, **Yeh RW**, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB Sr, Massaro JM, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. *JAMA Cardiol*. 2017 May 1;2(5):478-487. PMID: 28297015.
124. Young MN*, Elmariah S, Kennedy KF, Inglessis I, **Yeh RW**. Utilization and outcomes of transcatheter aortic valve replacement in the United States shortly after device approval. *Catheter Cardiovasc Interv*. 2017 Mar 22. doi: 10.1002/ccd.27018. [Epub ahead of print] PMID: 28326675.
125. Christakopoulos GE, Christopoulos G, Karpaliotis D, Alaswad K, **Yeh RW**, Jaffer FA, Wyman MR, Lombardi WL, Tarar MN, Grantham JA, Kandzari DE, Lembo N, Moses JW, Kirtane AJ, Parikh M, Green P, Finn M, Garcia S, Doing AH, Hatem R, Thompson CA, Banerjee S, Brilakis ES. Predictors of Excess Patient Radiation Exposure During Chronic Total Occlusion Coronary Intervention: Insights From a Contemporary Multicentre Registry. *Can J Cardiol*. 2017 Apr;33(4):478-484. doi: 10.1016/j.cjca.2016.11.002. Epub 2016 Nov 11. PMID: 28169091.
126. Karatasakis A, Iwnetu R, Danek BA, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Kandzari DE, Lembo NJ, Patel M, Mahmud E, Lombardi WL, Wyman RM, Grantham JA, Doing AH, Toma C, Choi JW, Uretsky BF, Moses JW, Kirtane AJ, Ali ZA, Parikh M, Karacsonyi J, Rangan BV, Thompson CA, Banerjee S, Brilakis ES. The Impact of Age and Sex on In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention. *J Invasive Cardiol*. 2017 Apr;29(4):116-122. Epub 2017 Jan 15. PMID: 28089997.
127. Strom JB*, McCabe JM, Waldo SW, Pinto DS, Kennedy KF, Feldman DN, **Yeh RW**. Management of Patients With Cardiac Arrest Complicating Myocardial Infarction in New York Before

- and After Public Reporting Policy Changes. *Circ Cardiovasc Interv.* 2017 May;10(5). pii: e004833. doi: 10.1161/CIRCINTERVENTIONS.116.004833. PMID: 28495895.
128. Secemsky EA*, **Yeh RW**, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM, Apruzzese PK, Mauri L; Dual Antiplatelet Therapy Study Investigators. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. *JACC Cardiovasc Interv.* 2017 May 8;10(9):942-954. doi: 10.1016/j.jcin.2017.02.013. PMID: 28473118.
129. Jovin IS, Shah RM, Patel DB, Rao SV, Baklanov DV, Moussa I, Kennedy KF, Secemsky EA, **Yeh RW**, Kontos MC, Vetrovec GW. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry. *JACC Cardiovasc Interv.* 2017 Jun 12;10(11):1102-1111. doi: 10.1016/j.jcin.2017.03.021. PMID: 28527778.
130. Karacsonyi J, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Mahmud E, Lombardi W, Wyman MR, Doing A, Moses JW, Kirtane A, Parikh M, Ali Z, Kandzari D, Lembo N, Garcia S, Danek BA, Karatasakis A, Resendes E, Kalsaria P, Rangan BV, Ungi I, Thompson CA, Banerjee S, Brilakis ES. Impact of Calcium on Chronic Total Occlusion Percutaneous Coronary Interventions. *Am J Cardiol.* 2017 Jul 1;120(1):40-46. doi: 10.1016/j.amjcard.2017.03.263. PMID: 28499595.
131. Strom JB*, Kramer DB, Wang Y, Shen C, Wasfy JH, Landon BE, Wilker EH, **Yeh RW**. Short-term rehospitalization across the spectrum of age and insurance types in the United States. *PLoS One.* 2017 Jul 10;12(7):e0180767. doi: 10.1371/journal.pone.0180767. eCollection 2017. PMID: 28700736.
132. Danek BA, Karatasakis A, Tajti P, Sandoval Y, Karpaliotis D, Alaswad K, Jaffer F, **Yeh RW**, Kandzari DE, Lembo NJ, Patel MP, Mahmud E, Choi JW, Doing AH, Lombardi WL, Wyman RM, Toma C, Garcia S, Moses JW, Kirtane AJ, Hatem R, Ali ZA, Parikh M, Karacsonyi J, Rangan BV, Khalili H, Burke MN, Banerjee S, Brilakis ES. Incidence, Treatment, and Outcomes of Coronary Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention. *Am J Cardiol.* 2017 Jul 24. pii: S0002-9149(17)31174-8. doi: 10.1016/j.amjcard.2017.07.010. [Epub ahead of print]. PMID: 28826896.
133. Sapontis J, Salisbury AC, **Yeh RW**, Cohen DJ, Hirai T, Lombardi W, McCabe JM, Karpaliotis D, Moses J, Nicholson WJ, Pershad A, Wyman RM, Spaedy A, Cook S, Doshi P, Federici R, Thompson CR, Marso SP, Nugent K, Gosch K, Spertus JA, Grantham JA. Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty: A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). *JACC Cardiovasc Interv.* 2017 Aug 14;10(15):1523-1534. doi: 10.1016/j.jcin.2017.05.065. PMID: 28797429.
134. Secemsky EA*, Gallagher R, Harkness J, Pomerantsev E, Gewirtz H, Jaffer FA, **Yeh RW**. Target Vessel Revascularization and Territory of Myocardial Ischemia in Patients With Chronic Total Occlusions. *J Am Coll Cardiol.* 2017 Aug 29;70(9):1196-1197. doi: 10.1016/j.jacc.2017.07.713. PMID: 28838371.
135. Butala NM, Secemsky EA, Wasfy JH, Kennedy KF, **Yeh RW**. Seasonality and Readmission after Heart Failure, Myocardial Infarction, and Pneumonia. *Health Serv Res.* 2017 Aug 31. doi: 10.1111/1475-6773.12747. [Epub ahead of print]. PMID: 28857149.
136. Grodzinsky A, Kosiborod M, Tang F, Jones PG, McGuire DK, Spertus JA, Beltrame JF, Jang JS, Goyal A, Butala NM, **Yeh RW**, Arnold SV. Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. *Circ Cardiovasc Qual Outcomes.* 2017 Sep;10(9). pii: e003553. doi: 10.1161/CIRCOUTCOMES.117.003553. PMID: 28904076.
137. Secemsky EA, Kirtane A, Bangalore S, Jovin IS, Patel D, Ferro EG, Wimmer NJ, Roe M, Dai D, Mauri L, **Yeh RW**. Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States. *Circ Cardiovasc Qual Outcomes.* 2017 Sep;10(9). pii:

e003741. doi: 10.1161/CIRCOUTCOMES.117.003741. PMID: 28855222.

138. O'Brien C*, Valsdottir L, Wasfy JH, Strom JB, Secemsky EA, Wang Y, **Yeh RW**. Comparison of 30-Day Readmission Rates After Hospitalization for Acute Myocardial Infarction in Men Versus Women. *Am J Cardiol*. 2017 Oct 1;120(7):1070-1076. doi: 10.1016/j.amjcard.2017.06.046. Epub 2017 Jul 14. PMID: 28781023.
139. Patel SM, Menon RV, Burke MN, Jaffer FA, **Yeh RW**, Vo M, Karpaliotis D, Azzalini L, Carlino M, Mashayekhi K, Galassi AR, Rinfret S, Ellis SG, Patel M, Rangan BV, Karatasakis A, Danek BA, Karacsonyi J, Resendes E, Banerjee S, Brilakis ES. Current Perspectives and Practices on Chronic Total Occlusion Percutaneous Coronary Interventions. *J Invasive Cardiol*. 2017 Oct 15. pii: JIC20171015-3. [Epub ahead of print]. PMID: 29035846.
140. Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, **Yeh RW**. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. *Circulation*. 2017 Dec 5;136(23):2210-2219. doi: 10.1161/CIRCULATIONAHA.117.028430. Epub 2017 Oct 30. PMID: 29084735.
141. **Yeh RW**, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, Mauri L; DAPT Study Investigators. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. *J Am Coll Cardiol*. 2017 Oct 31;70(18):2213-2223. doi: 10.1016/j.jacc.2017.09.011. PMID: 29073947.
142. Valle JA, Kaltenbach LA, Bradley SM, **Yeh RW**, Rao SV, Gurm HS, Armstrong EJ, Messenger JC, Waldo SW. Variation in the Adoption of Transradial Access for ST-Segment Elevation Myocardial Infarction: Insights From the NCDR CathPCI Registry. *JACC Cardiovasc Interv*. 2017 Nov 27;10(22):2242-2254. doi: 10.1016/j.jcin.2017.07.020. Epub 2017 Nov 1. PMID: 29102582.
143. Tajti P, Karatasakis A, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Mahmud E, Choi JW, Doing AH, Toma C, Uretsky B, Garcia S, Moses JW, Parikh M, Kirtane A, Ali ZA, Hatem R, Karacsonyi J, Danek BA, Rangan BV, Banerjee S, Ungi I, Brilakis ES. Retrograde CTO-PCI of Native Coronary Arteries Via Left Internal Mammary Artery Grafts: Insights From a Multicenter U.S. Registry. *J Invasive Cardiol*. 2017 Nov 15. pii: JIC20171115-1. [Epub ahead of print]. PMID: 29138364.
144. Blumenthal DM*, Mikhael B, Lawler PR, **Yeh RW**, Metlay JP, Dudzinski DM. Personal and Professional Characteristics of U.S. Dual-Boarded Critical Care Cardiologists in 2015. *Crit Care Med*. 2017 Dec;45(12):e1292-e1296. doi: 10.1097/CCM.0000000000002766. PMID: 29023259.
145. Secemsky EA*, Schermerhorn M, Carroll BJ, Kennedy KF, Shen C, Valsdottir LR, Landon B, **Yeh RW**. Readmissions After Revascularization Procedures for Peripheral Arterial Disease: A Nationwide Cohort Study. *Ann Intern Med*. 2017 Dec 5;1-8. doi: 10.7326/M17-1058. [Epub ahead of print]. PMID: 29204656.
 - Awarded AHRQ-AcademyHealth HCUP Article of the Year, 2017
146. Hess PL, Kennedy K, Cowherd M, Virani SS, Masoudi FA, Navar AM, **Yeh RW**, Ho PM, Maddox TM. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. *Am Heart J*. 2018 Jan;195:151-152. doi: 10.1016/j.ahj.2017.09.004. Epub 2017 Sep 9. No abstract available. PMID: 2922464.
147. Elmariah S, Doros G, Benavente OR, Bhatt DL, Connolly SJ, Yusuf S, Steinhubl SR, Liu Y, Hsieh WH, **Yeh RW**, Mauri L. Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. *Circ Cardiovasc Interv*. 2018 Jan;11(1):e005795. doi: 10.1161/CIRCINTERVENTIONS.117.005795. PMID: 29311290.
148. Ko SQ*, Strom JB, Shen C, **Yeh RW**. Mortality, Length of Stay, and Cost of Weekend Admissions. *J Hosp Med*. 2018 Jan 25. doi: 10.12788/jhm.2906. [Epub ahead of print] PMID: 29370319.

149. Strom JB*, Zhao Y, Shen C, Chung M, Pinto DS, Popma JJ, **Yeh RW**. National Trends, Predictors of Use, and In-Hospital Outcomes in the Mechanical Circulatory Support for Cardiogenic Shock. *EuroIntervention*. 2018 Feb 6. pii: EIJ-D-17-00947. doi: 10.4244/EIJ-D-17-00947. [Epub ahead of print] PMID: 29400657.
150. Jena AB, Olenski A, Blumenthal DM, **Yeh RW**, Goldman DP, Romley. Acute Myocardial Infarction Mortality During Dates of National Interventional Cardiology Meetings. *J Am Heart Assoc*. 2018 Mar 9;7(6). pii: e008230. doi: 10.1161/JAHA.117.008230. PMID: 29523525
151. Wadhwa RK*, Joynt Maddox KE, Wang Y, Shen C, Bhatt DL, **Yeh RW**. Association Between Thirty-day Episode Payments and Acute Myocardial Infarction Outcomes Among Medicare Beneficiaries. *Circulation: Cardiovascular Outcomes and Quality of Care. Circ Cardiovasc Qual Outcomes*. 2018 Mar;11(3):e004397. doi: 10.1161/CIRCOUTCOMES.117.004397. PMID: 2953088
152. Butala NM*, Kramer DB, Shen C, Strom JB, Kennedy KF, Wang Y, Wasfy JH, **Yeh RW**. Applicability of publicly-reported hospital readmission measures to unreported conditions and patient populations: a cross-sectional all-payer study. *Annals of Internal Medicine*. 2018 May 1;168(9):631-639. doi: 10.7326/M17-1492. Epub 2018 Mar 27. PMID: 29582086
153. Faridi KF*, Popma JJ, Strom JB, Shen C, Choi E, **Yeh RW**. Utilization, In-Hospital Mortality, and 30-Day Readmission After Percutaneous Mitral Valve Repair in the United States Shortly After Device Approval. *Am J Cardiol*. 2018 Mar 1. pii: S0002-9149(18)30252-2. doi: 10.1016/j.amjcard.2018.02.016. [Epub ahead of print] PMID: 29627105
154. Tajti P, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Toma C, Smith AJC, Uretsky B, Holper E, Wyman RM, Kandzari DE, Garcia S, Krestyaninov O, Khelimskii D, Koutouzis M, Tsiafoutis I, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Doshi D, Rangan BV, Ungi I, Banerjee S, Brilakis ES. The Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: Update From the PROGRESS CTO Registry. *JACC Cardiovasc Interv*. 2018 Apr 24. pii: S1936-8798(18)30653-8. doi: 10.1016/j.jcin.2018.02.036. [Epub ahead of print] PMID: 29706508
155. Wadhwa RK*, Joynt Maddox KE, Wang Y, Shen C, **Yeh RW**. 30-day Episode Payments and Heart Failure Outcomes Among Medicare Beneficiaries. *JACC: Heart Failure*. ePub ahead of print April 2018.
156. Wadhwa RK*, Shen C, Secemsky EA, Strom JB, **Yeh RW**. State Variation in the Use of Non-Acute Coronary Angiograms and Coronary Revascularization Procedures. *JACC Cardiovasc Interv*. 2018 May 14;11(9):912-913. doi: 10.1016/j.jcin.2018.03.039. PMID: 29747922.
157. Tamez H*, Génereux P, **Yeh RW**, Amin AP, Fan W, White HD, Kirtane AJ, Stone GW, Gibson CM, Harrington RA, Bhatt DL, Pinto DS; CHAMPION PHOENIX ECONOMICS Investigators. Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. *Catheter Cardiovasc Interv*. 2018 May 4. doi: 10.1002/ccd.27638. PMID: 29726596.
158. Secemsky EA*, Rosenfield K, Kennedy KF, Jaff M, **Yeh RW**. High Burden of 30-Day Readmissions After Acute Venous Thromboembolism in the United States. *J Am Heart Assoc*. 2018 Jun 26;7(13). pii: e009047. doi: 10.1161/JAHA.118.009047. PMID: 29945913.
159. Blumenthal DM*, Valsdottir LR, Zhao Y, Shen C, Kirtane AJ, Pinto DS, Resnic FS, Maddox KEJ, Wasfy JH, Mehran R, Rosenfield K, **Yeh RW**. A Survey of Interventional Cardiologists' Attitudes and Beliefs About Public Reporting of Percutaneous Coronary Intervention. *JAMA Cardiol*. 2018 May 9. doi: 10.1001/jamacardio.2018.1095. PMID: 29801157.
160. Mauri L, Kirtane AJ, Windecker S, **Yeh RW**, Dauerman HL, Price MJ, Christen T, Allocco DJ, Meredith IT, Kereiakes DJ. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary

- intervention. *Am Heart J.* 2018 Aug 17;205:110-117. doi: 10.1016/j.ahj.2018.08.004. [Epub ahead of print] PMID: 30218844.
161. Tajti P, Karatasakis A, Danek BA, Alaswad K, Karpaliotis D, Jaffer FA, Choi JW, **Yeh RW**, Patel M, Mahmud E, Burke MN, Krestyaninov O, Khelimskii D, Toma C, Doing AH, Uretsky B, Koutouzis M, Tsiafoutis I, Wyman RM, Garcia S, Holper E, Xenogiannis I, Rangan BV, Banerjee S, Ungi I, Brilakis ES. In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease. *J Invasive Cardiol.* 2018 Sep 15. pii: JIC2018915-3. [Epub ahead of print] PMID: 30218557.
162. Tajti P, Alaswad K, Karpaliotis D, Jaffer FA, **Yeh RW**, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Toma C, Uretsky B, Holper E, Wyman RM, Kandzari DE, Garcia S, Krestyaninov O, Khelimskii D, Koutouzis M, Tsiafoutis I, Jaber W, Samady H, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Doshi D, Xenogiannis I, Rangan BV, Ungi I, Banerjee S, Brilakis ES. In-hospital Outcomes of Attempting More Than One Chronic Total Coronary Occlusion Through Percutaneous Intervention During the Same Procedure. *Am J Cardiol.* 2018 Aug 1;122(3):381-387. doi: 10.1016/j.amjcard.2018.04.021. Epub 2018 May 1. PMID: 30201106.
163. Ko SQ*, Valsdottir LR, Strom JB, Cheng YC, Hirayama A, Liu PH, Yanagisawa N, Yen H, Shen C, **Yeh RW**. Meta-Analysis of Bleeding Risk Prediction Scores in Patients After Percutaneous Coronary Intervention on Dual Antiplatelet Therapy. *Am J Cardiol.* 2018 Dec 1;122(11):1843-1852. doi: 10.1016/j.amjcard.2018.08.025. Epub 2018 Sep 8. PMID: 30309627.
164. Kundi H, Strom JB, Valsdottir LR, Elmariah S, Popma JJ, Shen C, **Yeh RW**. Trends in Isolated Surgical Aortic Valve Replacement According to Hospital-Based Transcatheter Aortic Valve Replacement Volumes. *JACC Cardiovasc Interv.* 2018 Nov 12;11(21):2148-2156. doi: 10.1016/j.jcin.2018.07.002. Epub 2018 Oct 17. PMID: 30343022.
165. Kundi H*, Valsdottir LR, Popma JJ, Cohen DJ, Strom JB, Pinto DS, Shen C, **Yeh RW**. Impact of a Claims-Based Frailty Indicator on the Prediction of Long-Term Mortality After Transcatheter Aortic Valve Replacement in Medicare Beneficiaries. *Circ Cardiovasc Qual Outcomes.* 2018 Oct;11(10):e005048. doi: 10.1161/CIRCOUTCOMES.118.005048. PMID: 30354574
166. Berry NC, Kereiakes DJ, **Yeh RW**, Steg PG, Cutlip DE, Jacobs AK, Abbott JD, Hsieh WH, Massaro JM, Mauri L; DAPT Study Investigators. Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. *Circ Cardiovasc Interv.* 2018 Aug;11(8):e005308. doi: 10.1161/CIRCINTERVENTIONS.117.005308. PMID: 30354781
167. Vidula MK*, McCarthy CP, Butala NM, Kennedy KF, Wasfy JH, **Yeh RW**, Secemsky EA. Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy. *PLoS One.* 2018 Oct 31;13(10):e0205457. doi: 10.1371/journal.pone.0205457. eCollection 2018. PMID: 30379868
168. Xenogiannis I, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Toma C, Smith AJC, Uretsky B, Krestyaninov O, Khelimskii D, Holper E, Potluri S, Wyman RM, Kandzari DE, Garcia S, Koutouzis M, Tsiafoutis I, Jaber W, Samady H, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Doshi D, Tajti P, Rangan BV, Abdullah S, Banerjee S, Brilakis ES. Comparison Between Traditional and Guide-Catheter Extension Reverse Controlled Antegrade Dissection and Retrograde Tracking: Insights From the PROGRESS-CTO Registry. *J Invasive Cardiol.* 2018 Nov 11. pii: JIC20181111-3. [Epub ahead of print] PMID: 30418166.
169. Kundi H*, Popma JJ, Cohen DJ, Liu DC, Laham RJ, Pinto DS, Chu LM, Strom JB, Shen C, **Yeh RW**. Prevalence and Outcomes of Isolated Tricuspid Valve Surgery Among Medicare Beneficiaries. *Am J Cardiol.* 2018 Sep 27. pii: S0002-9149(18)31837-X. doi: 10.1016/j.amjcard.2018.09.016. [Epub ahead of print] PMID: 30442362.
170. Kundi H*, Popma JJ, Valsdottir LR, Shen C, Faridi KF, Pinto DS, **Yeh RW**. The Value of Claims-Based Nontraditional Risk Factors in Predicting Long-term Mortality After MitraClip Procedure. *Can J*

Cardiol. 2018 Dec;34(12):1648-1654. doi: 10.1016/j.cjca.2018.10.002. Epub 2018 Oct 13. PMID: 30527154.

171. Wadhwa RK*, Choi E, Shen C, **Yeh RW**, Joynt Maddox KE. Trends, Causes, and Outcomes of Hospitalizations for Homeless Individuals: A Retrospective Cohort Study. *Med Care*. 2018 Nov 19. doi: 10.1097/MLR.0000000000001015. [Epub ahead of print] PMID: 30461584.
172. Kundi H*, Popma JJ, Khabbaz KR, Chu LM, Strom JB, Valsdottir LR, Shen C, **Yeh RW**. Association of Hospital Surgical Aortic Valve Replacement Quality With 30-Day and 1-Year Mortality After Transcatheter Aortic Valve Replacement. *JAMA Cardiol*. 2018 Dec 5. doi: 10.1001/jamacardio.2018.4051. [Epub ahead of print] PMID: 30516798.
173. Chung M*, Zhao Y, Strom JB, Shen C, **Yeh RW**. Extracorporeal Membrane Oxygenation Use in Cardiogenic Shock: Impact of Age on In-Hospital Mortality, Length of Stay, and Costs. *Crit Care Med*. 2018 Dec 21. doi: 10.1097/CCM.0000000000003631. [Epub ahead of print] PMID: 30585830.
174. Wadhwa RK*, Joynt Maddox KE, Wasfy JH, Haneuse S, Shen C, **Yeh RW**. Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia. *JAMA*. 2018 Dec 25;320(24):2542-2552. doi: 10.1001/jama.2018.19232. PMID: 30575880.
175. Blumenthal DM*, Strom JB*, Valsdottir LR, Howard SE, Wagle NW, Ho KKL, Horn DM, O'Keefe SM, Wasfy JH, Metlay JP, **Yeh RW**. Patient-Reported Outcomes in Cardiology. *Circ Cardiovasc Qual Outcomes*. 2018 Nov;11(11):e004794. doi: 10.1161/CIRCOUTCOMES.118.004794. No abstract available. PMID: 30571330.
176. Wadhwa RK*, Sukul D, Secemsky EA, Shen C, Gurm HS, Boden WE, **Yeh RW**. Temporal Trends in Unstable Angina Diagnosis Codes for Outpatient Percutaneous Coronary Interventions. *JAMA Intern Med*. 2018 Dec 17. doi: 10.1001/jamainternmed.2018.5124. [Epub ahead of print] No abstract available. PMID: 30556822.
177. **Yeh RW**, Valsdottir LR, Yeh MW, Shen C, Kramer DB, Strom JB, Secemsky EA, Healy JL, Domeier RM, Kazi DS, Nallamothu BK; PARACHUTE Investigators. Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. *BMJ*. 2018 Dec 13;363:k5094. doi: 10.1136/bmj.k5094. PMID: 30545967.
 - Named one of the 5 most important BMJ papers of the decade by BMJ editors.
 - Highest Altmetric score and most downloaded article for any BMJ publication.
178. Valle JA*, Tamez H, Abbott JD, Moussa ID, Messenger JC, Waldo SW, Kennedy KF, Masoudi FA, **Yeh RW**. Contemporary Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention in the United States: An Analysis of the National Cardiovascular Data Registry Research to Practice Initiative. *JAMA Cardiol*. 2019 Jan 2. doi: 10.1001/jamacardio.2018.4376. [Epub ahead of print] PMID: 30601910.
179. Strom JB*, Zhao Y, Shen C, Chung M, Pinto DS, Popma JJ, Cohen DJ, **Yeh RW**. Hospital Variation in the Utilization of Short-Term Nondurable Mechanical Circulatory Support in Myocardial Infarction Complicated by Cardiogenic Shock. *Circ Cardiovasc Interv*. 2019 Jan;12(1):e007270. doi: 10.1161/CIRCINTERVENTIONS.118.007270. PMID: 30608880.
180. Galper BZ*, Reynolds MR, Garg P, Secemsky EA, Valsdottir LR, Cohen DJ, **Yeh RW**. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. *Coron Artery Dis*. 2019 Jan 22. doi: 10.1097/MCA.0000000000000694. [Epub ahead of print] PMID: 30676386.
181. Wadhwa RK*, Bhatt DL, Wang TY, Lu D, Lucas J, Figueroa JF, Garratt KN, **Yeh RW**, Joynt Maddox KE. Association of State Medicaid Expansion With Quality of Care and Outcomes for Low-

- Income Patients Hospitalized With Acute Myocardial Infarction. *JAMA Cardiol.* 2019 Jan 16. doi: 10.1001/jamacardio.2018.4577. PMID: 30649146.
182. Secemsky EA*, Ferro EG, Rao SV, Kirtane A, Tamez H, Zakrofsky P, Wojdyla D, Bradley SM, Cohen DJ, **Yeh RW**. Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: The National Cardiovascular Data Registry CathPCI Registry. *JAMA Cardiol.* 2019 Jan 9. doi: 10.1001/jamacardio.2018.4472. [Epub ahead of print] PMID: 30624549.
183. Sandoval Y, Tajti P, Karatasakis A, Burke MN, Danek BA, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Mahmud E, Krestyaninov O, Khelimskii D, Choi JW, Doing AH, Toma C, Wyman RM, Uretsky B, Garcia S, Koutouzis M, Tsiafoutis I, Holper E, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Doshi D, Kandzari DE, Karacsonyi J, Rangan BV, Thompson C, Banerjee S, Brilakis ES. Frequency and Outcomes of Ad Hoc Versus Planned Chronic Total Occlusion Percutaneous Coronary Intervention: Multicenter Experience. *J Invasive Cardiol.* 2019 Jan 15. pii: JIC2019115-2. [Epub ahead of print] PMID: 30643040.
184. Ferro EG*, Secemsky EA, Wadhwa RK, Choi E, Strom JB, Wasfy JH, Wang Y, Shen C, **Yeh RW**. Patient Readmission Rates For All Insurance Types After Implementation Of The Hospital Readmissions Reduction Program. *Health Aff (Millwood).* 2019 Apr;38(4):585-593. doi: 10.1377/hlthaff.2018.05412. PMID: 30933582.
185. Wadhwa RK*, O'Brien CW, Joynt Maddox KE, Ho KKL, Pinto DS, Resnic FS, Shah PB, **Yeh RW**. Public Reporting of Percutaneous Coronary Intervention Outcomes: Institutional Costs and Physician Burden. *J Am Coll Cardiol.* 2019 Mar 11. pii: S0735-1097(19)33940-3. doi: 10.1016/j.jacc.2019.03.014. [Epub ahead of print] No abstract available. PMID: 30885686.
186. **Yeh RW**, Tamez H, Secemsky EA, Grantham JA, Sapontis J, Spertus JA, Cohen DJ, Nicholson WJ, Gosch K, Jones PG, Valsdottir LR, Bruckel J, Lombardi WL, Jaffer FA. Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention: The OPEN-CTO Registry. *JACC Cardiovasc Interv.* 2019 Mar 9. pii: S1936-8798(18)32550-0. doi: 10.1016/j.jcin.2018.12.029. [Epub ahead of print] PMID: 30878475.
187. Tajti P, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Toma C, Smith AJC, Uretsky B, Holper E, Potluri S, Wyman RM, Kandzari DE, Garcia S, Krestyaninov O, Khelimskii D, Koutouzis M, Tsiafoutis I, Jaber W, Samady H, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Doshi D, Xenogiannis I, Stanberry LI, Rangan BV, Ungi I, Banerjee S, Brilakis ES. In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Interventions in Patients With Prior Coronary Artery Bypass Graft Surgery. *Circ Cardiovasc Interv.* 2019 Mar;12(3):e007338. doi: 10.1161/CIRCINTERVENTIONS.118.007338. PMID: 30871357.
188. Secemsky EA*, Kundi H, Weinberg I, Schermerhon M, Beckman JA, Parikh SA, Jaff MR, Mustapha J, Rosenfield K, **Yeh RW**. Drug-Eluting Stent Implantation and Long-term Survival following Peripheral Artery Revascularization. *J Am Coll Cardiol.* 2019 Feb 21. pii: S0735-1097(19)30594-7. doi: 10.1016/j.jacc.2019.02.020. [Epub ahead of print] No abstract available. PMID: 30831175.
189. Xenogiannis I, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Toma C, Smith AJC, Uretsky B, Krestyaninov O, Khelimskii D, Holper E, Potluri S, Wyman RM, Kandzari DE, Garcia S, Koutouzis M, Tsiafoutis I, Khatri JJ, Jaber W, Samady H, Jefferson BK, Patel T, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Doshi D, Tajti P, Rangan BV, Abdullah S, Banerjee S, Brilakis ES. Usefulness of Atherectomy in Chronic Total Occlusion Interventions (from the PROGRESS-CTO Registry). *Am J Cardiol.* 2019 Feb 11. pii: S0002-9149(19)30186-9. doi: 10.1016/j.amjcard.2019.01.054. [Epub ahead of print] PMID: 30798947.
190. Tajti P, Alaswad K, Karpaliotis D, Jaffer FA, **Yeh RW**, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Toma C, Smith AJC, Uretsky BF, Holper E, Potluri S, Wyman RM, Kandzari DE, Garcia S, Krestyaninov O, Khelimskii D, Koutouzis M, Tsiafoutis I, Khatri JJ, Jaber W, Samady H, Jefferson B, Patel T, Abdullah S, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Doshi D,

- Xenogiannis I, Stanberry LI, Rangan BV, Ungi I, Banerjee S, Brilakis ES. Procedural Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions Via the Radial Approach: Insights From an International Chronic Total Occlusion Registry. *JACC Cardiovasc Interv.* 2019 Feb 25;12(4):346-358. doi: 10.1016/j.jcin.2018.11.019. PMID: 30784639.
191. Secemsky EA*, Kundi H, Weinberg I, Jaff MR, Krawisz A, Parikh SA, Beckman JA, Mustapha J, Rosenfield K, **Yeh RW**. Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices. *JAMA Cardiol.* 2019 Feb 12. doi: 10.1001/jamacardio.2019.0325. [Epub ahead of print]. PMID: 30747949.
192. Strom JB*, Tamez H, Zhao Y, Valsdottir LR, Curtis J, Brennan JM, Shen C, Popma JJ, Mauri L, **Yeh RW**. Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. *Am Heart J. Am Heart J.* 2019 Jun;212:64-71. doi: 10.1016/j.ahj.2019.02.007. PMID: 30953936. PMCID: 6535119.
193. Kundi H*, Popma JJ, Reynolds MR, Strom JB, Pinto DS, Valsdottir LR, Shen C, Choi E, **Yeh RW**. Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort. *Eur Heart J.* 2019 Apr 11. pii: ehz187. doi: 10.1093/eurheartj/ehz187. [Epub ahead of print] PMID: 30977798
194. Nathan AS*, Shah RM, Khatana SA, Dayoub E, Chatterjee P, Desai ND, Waldo SW, **Yeh RW**, Groeneveld PW, Giri J. Effect of Public Reporting on the Utilization of Coronary Angiography After Out-of-Hospital Cardiac Arrest. *Circ Cardiovasc Interv.* 2019 Apr;12(4):e007564. doi: 10.1161/CIRCINTERVENTIONS.118.007564. PMID: 30998398.
195. Chau KH, Kennedy KF, Messenger JC, Garratt KN, Maddox TM, **Yeh RW**, Kirtane AJ. Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice: An NCDR Registry to Practice Project. *JAMA Cardiol.* 2019 May 8. doi: 10.1001/jamacardio.2019.0388. PMID: 31066860.
196. Nathan AS*, Khatana SAM, **Yeh RW**, Groeneveld PW, Giri J. Hospital-Specific Mortality for Acute Myocardial Infarction Versus Emergency Percutaneous Coronary Intervention in New York State. *JACC Cardiovasc Interv.* 2019 May 13;12(9):898-899. doi: 10.1016/j.jcin.2019.02.045. PMID: 31072516.
197. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, **Yeh RW**, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. *Circulation.* 2019 Jul 16;140(3):240-261. doi: 10.1161/CIRCULATIONAHA.119.040167. Epub 2019 May 22. PMID: 31116032.
198. Valley TS, Iwashyna TJ, Cooke CR, Sinha SS, Ryan AM, **Yeh RW**, Nallamothu BK. Intensive care use and mortality among patients with ST elevation myocardial infarction: retrospective cohort study. *BMJ.* 2019 Jun 4;365:l1927. doi: 10.1136/bmj.l1927. PMID: 31164326.
199. Tripathi B, **Yeh RW**, Bavishi CP, Sardar P, Atti V, Mukherjee D, Bashir R, Abbott JD, Giri J, Chatterjee S. Etiologies, trends, and predictors of readmission in ST-elevation myocardial infarction patients undergoing multivessel percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2019 Jun 4. doi: 10.1002/ccd.28344. [Epub ahead of print] PMID: 31165573.
200. Brilakis ES, Mashayekhi K, Tsuchikane E, et al. Abi Rafeh N, Alaswad K, Araya M, Avran A, Azzalini L, Babunashvili AM, Bayani B, Bhindi R, Boudou N, Boukhris M, Božinović NŽ, Bryniarski L, Bufe A, Buller CE, Burke MN, Büttner HJ, Cardoso P, Carlino M, Christiansen EH, Colombo A, Croce K, Damas de Los Santos F, De Martini T, Dens J, Di Mario C, Dou K, Egred M, ElGuindy AM, Escaned J, Furkalo S, Gagnor A, Galassi AR, Garbo R, Ge J, Goel PK, Goktekin O, Grancini L, Grantham JA, Hanratty C, Harb S, Harding SA, Henriques JPS, Hill JM, Jaffer FA, Jang Y, Jussila R,

- Kalnins A, Kalyanasundaram A, Kandzari DE, Kao HL, Karpaliotis D, Kassem HH, Knaapen P, Kornowski R, Krestyaninov O, Kumar AVG, Laanmets P, Lamelas P, Lee SW, Lefevre T, Li Y, Lim ST, Lo S, Lombardi W, McEntegart M, Munawar M, Navarro Lecaro JA, Ngo HM, Nicholson W, Olivecrona GK, Padilla L, Postu M, Quadros A, Quesada FH, Prakasa Rao VS, Reifart N, Saghatelian M, Santiago R, Sianos G, Smith E, C Spratt J, Stone GW, Strange JW, Tammam K, Ungi I, Vo M, Vu VH, Walsh S, Werner GS, Wollmuth JR, Wu EB, Wyman RM, Xu B, Yamane M, Ybarra LF, **Yeh RW**, Zhang Q, Rinfret S. Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. *Circulation*. 2019 Jul 30;140(5):420-433. doi: 10.1161/CIRCULATIONAHA.119.039797. Epub 2019 Jul 29. PMID: 31356129.
201. Xenogiannis I, Karpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Toma C, Uretsky B, Krestyaninov O, Khelimskii D, Holper E, Potluri S, Wyman RM, Kandzari DE, Garcia S, Koutouzis M, Tsiafoutis I, Khatri JJ, Jaber W, Samady H, Jefferson BK, Patel T, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Gkargkoulas F, Tajti P, Hall AB, Rangan BV, Abdullah S, Banerjee S, Brilakis ES. Impact of concomitant treatment of non-chronic total occlusion lesions at the time of chronic total occlusion intervention. *Int J Cardiol*. 2019 Jul 3. pii: S0167-5273(18)37361-3. doi: 10.1016/j.ijcard.2019.06.077. PMID: 31301862.
202. Xenogiannis I, Karpaliotis D, Alaswad K, Basir MB, **Yeh RW**, Tamez H, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Khatri JJ, Sheikh AM, Malik BA, Greene ME, Abi Rafeh N, Maalouf A, Abou Jaoudeh F, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Gkargkoulas F, Russo J, Hakemi E, Tajti P, Hall AB, Vemmou E, Nikolakopoulos I, Rangan BV, Abdullah S, Banerjee S, Brilakis ES. Left Main Chronic Total Occlusion Percutaneous Coronary Intervention: A Case Series. *J Invasive Cardiol*. 2019 Jul;31(7):E220-E225. PMID: 31257217.
203. Kundi H*, Cohen DJ, Strom JB, Valsdottir L, Shen C, Choi E, Popma JJ, **Yeh RW**. Trends in isolated aortic valve replacement in the United States in the early phase of expansion of TAVR. *Int J Cardiol*. 2019 Oct 1;292:68-72. doi: 10.1016/j.ijcard.2019.06.061. Epub 2019 Jun 22. PMID: 31255451.
204. Khatana SAM*, Bhatla A, Nathan AS, Giri J, Shen C, Kazi DS, **Yeh RW**, Groeneveld PW. Association of Medicaid Expansion With Cardiovascular Mortality. *JAMA Cardiol*. 2019 Jul 1;4(7):671-679. doi: 10.1001/jamacardio.2019.1651. Erratum in: *JAMA Cardiol*. 2019 Jul 1;4(7):714. PMID: 31166575.
205. Wadhera RK*, Joynt Maddox KE, Kazi DS, Shen C, **Yeh RW**. Hospital revisits within 30 days after discharge for medical conditions targeted by the Hospital Readmissions Reduction Program in the United States: national retrospective analysis. *BMJ*. 2019 Aug 12;366:l4563. doi: 10.1136/bmj.l4563. PMID: 31405902.
206. Faridi KF, Rymer JA, Rao SV, Dai D, Wojdyla D, **Yeh RW**, Wang TY. Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry. *Am Heart J*. 2019 Jul 13;216:53-61. doi: 10.1016/j.ahj.2019.07.004. [Epub ahead of print] PMID: 31401443.
207. Young MN*, Secemsky EA, Kaltenbach LA, Jaffer FA, Grantham JA, Rao SV, **Yeh RW**. Examining the Operator Learning Curve for Percutaneous Coronary Intervention of Chronic Total Occlusions. *Circ Cardiovasc Interv*. 2019 Aug;12(8):e007877. doi: 10.1161/CIRCINTERVENTIONS.119.007877. Epub 2019 Aug 16. PMID: 31416356.
208. Kundi H*, Faridi KF, Wang Y, Wadhera RK, Valsdottir LR, Popma JJ, Kramer DB, **Yeh RW**. Geographic Patterns of Growth for Transcatheter Aortic Valve Replacement in the United States. *Circulation*. 2019 Sep 10;140(11):969-971. doi: 10.1161/CIRCULATIONAHA.119.040788. Epub 2019 Sep 9. No abstract available. PMID: 31498696.
209. Kundi H*, Wadhera RK, Strom JB, Valsdottir LR, Shen C, Kazi DS, **Yeh RW**. Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly Adults. *JAMA Cardiol*. 2019 Sep 25. doi: 10.1001/jamacardio.2019.3511. PMID: 31553402.

210. Wasfy JH, Bhambhani V, Healy EW, Choirat C, Dominici F, Wadhera RK, Shen C, Wang Y, **Yeh RW**. Relative Effects of the Hospital Readmissions Reduction Program on Hospitals That Serve Poorer Patients. *Med Care*. 2019 Dec;57(12):968-976. doi: 10.1097/MLR.0000000000001207. PMID: 31567860.
211. Kundi H*, Wadhera RK, Strom JB, Valsdottir LR, Shen C, Kazi DS, **Yeh RW**. Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly Adults. *JAMA Cardiol*. 2019 Sep 25. doi: 10.1001/jamacardio.2019.3511. PMID: 31553402.
212. Fazel R*, Vilain KA, Cohen DJ, **Yeh RW**. Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model. *Coron Artery Dis*. 2019 Oct 23. doi: 10.1097/MCA.0000000000000810. [Epub ahead of print] PMID: 31658137.
213. Stefanescu Schmidt AC, Steg PG, **Yeh RW**, Kereiakes DJ, Tanguay JF, Hsieh WH, Massaro JM, Mauri L, Cutlip DE; DAPT Investigators. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). *Am J Cardiol*. 2019 Dec 15;124(12):1813-1820. doi: 10.1016/j.amjcard.2019.09.006. Epub 2019 Sep 26. PMID: 31653353
214. Beyer SE, Shanafelt C, Pinto DS, Weinstein JL, Aronow HD, Weinberg I, **Yeh RW**, Secemsky EA, Carroll BJ. 2. Utilization and Outcomes of Thrombolytic Therapy for Acute Pulmonary Embolism: A Nationwide Cohort Study. *Chest*. 2019 Nov 26. pii: S0012-3692(19)34284-9. doi: 10.1016/j.chest.2019.10.049. [Epub ahead of print] PMID: 31783016.
215. Anderson JD, Wadhera RK, Joynt Maddox KE, Wang Y, Shen C, Stevens JP, **Yeh RW**. Thirty-day Spending and Outcomes for an Episode of Pneumonia Care Among Medicare Beneficiaries. *Chest*. 2019 Nov 21. pii: S0012-3692(19)34221-7. doi: 10.1016/j.chest.2019.11.003. [Epub ahead of print] PMID: 31759965.
216. Kelbæk H, **Yeh RW**, Engstrøm T, Neumann FJ, Serruys PW, Windecker S, Belardi J, Qiao S, Xu B, Liu M, Silber S. Five-year clinical outcomes for the Resolute zotarolimus-eluting stent in total coronary occlusions. *EuroIntervention*. 2019 Nov 19. pii: EIJ-D-19-00866. doi: 10.4244/EIJ-D-19-00866. [Epub ahead of print] PMID: 31746760.
217. Wadhera RK*, Khatana SAM, Choi E, Jiang G, Shen C, **Yeh RW**, Joynt Maddox KE. Disparities in Care and Mortality Among Homeless Adults Hospitalized for Cardiovascular Conditions. *JAMA Intern Med*. 2019 Nov 18. doi: 10.1001/jamainternmed.2019.6010. [Epub ahead of print] PMID: 31738826.
218. Strom JB*, Zhao Y, Faridi KF, Tamez H, Butala NM, Valsdottir LR, Curtis J, Brennan JM, Shen C, Boulware M, Popma JJ, **Yeh RW**. Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement: Findings From the EXTEND Study. *Circ Cardiovasc Interv*. 2019 Nov;12(11):e008231. doi: 10.1161/CIRCINTERVENTIONS.119.008231. Epub 2019 Nov 7. PMID: 31694411.
219. Yang JX, Stevenson MJ, Valsdottir L, Ho K, Spertus JA, **Yeh RW**, Strom JB. Association between procedure appropriateness and patient-reported outcomes after percutaneous coronary intervention. *Heart*. 2019 Dec 19. pii: heartjnl-2019-315835. doi: 10.1136/heartjnl-2019-315835. [Epub ahead of print] PMID: 31857352.
220. Xenogiannis I, Gkargkoulas F, Karpaliotis D, Alaswad K, Krestyaninov O, Khelimskii D, Choi JW, Jaffer FA, Patel M, Mahmud E, Khatri JJ, Kandzari DE, Doing AH, Dattilo P, Toma C, Koutouzis M, Tsiafoutis I, Uretsky B, **Yeh RW**, Tamez H, Wyman RM, Jefferson BK, Patel T, Jaber W, Samady H, Sheikh AM, Malik BA, Holper E, Potluri S, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Hall AB, Vemmou E, Nikolakopoulos I, Dargham BB, Rangan BV, Abdullah S, Garcia S, Banerjee S, Burke MN, Brilakis ES. The Impact of Peripheral Artery Disease in Chronic Total Occlusion Percutaneous Coronary Intervention (Insights From PROGRESS-CTO Registry). *Angiology*. 2019 Dec

17:3319719895178. doi: 10.1177/0003319719895178. [Epub ahead of print] PMID: 31845593.

221. Carroll BJ, Schermerhorn M, Kennedy KF, Swerdlow N, Soriano KM, **Yeh RW**, Secemsky EA. Readmissions after acute type B aortic dissection. *J Vasc Surg.* 2019 Dec 12. pii: S0741-5214(19)32387-0. doi: 10.1016/j.jvs.2019.08.280. [Epub ahead of print] PMID: 31839347.
222. Xenogiannis I, Gkargkoulas F, Karpaliotis D, Krestyaninov O, Khelinskii D, Jaffer FA, Khatri JJ, Kandzari DE, Wyman RM, Doing AH, Dattilo P, Toma C, **Yeh RW**, Tamez H, Choi JW, Jaber W, Samady H, Sheikh AM, Potluri S, Patel M, Mahmud E, Elbaruni B, Love MP, Koutouzis M, Tsiafoutis I, Jefferson BK, Patel T, Uretsky B, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Hall AB, Megaly MS, Vemmou E, Nikolakopoulos I, Rangan BV, Morley PW, Bou Dargham B, Abdullah S, Garcia S, Banerjee S, Burke MN, Brilakis ES, Alaswad K. Retrograde Chronic Total Occlusion Percutaneous Coronary Intervention via Saphenous Vein Graft. *JACC Cardiovasc Interv.* 2020 Feb 24;13(4):517-526. doi: 10.1016/j.jcin.2019.10.028. PMID: 32081243.
223. Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, **Yeh RW**, Arnold SV, Sperry BW, Maurer MS, Shah SJ. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. *Circulation.* 2020 Feb 12. doi: 10.1161/CIRCULATIONAHA.119.045093. [Epub ahead of print] PMID: 32078382.
224. Wadhwa RK*, Vaduganathan M, Jiang GY, Song Y, Xu J, Shen C, Bhatt DL, **Yeh RW**, Fonarow GC. Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. *JAMA Cardiol.* 2020 Feb 19. doi: 10.1001/jamacardio.2020.0001. [Epub ahead of print] PMID: 32074242.
225. Dhruva SS, Parzynski CS, Gamble GM, Curtis JP, Desai NR, **Yeh RW**, Masoudi FA, Kuntz R, Shaw RE, Marinac-Dabic D, Sedrakyan A, Normand ST, Krumholz HM, Ross JS. Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. *J Am Heart Assoc.* 2020 Feb 18;9(4):e013606. doi: 10.1161/JAHA.119.013606. Epub 2020 Feb 16. PMID: 32063087.
226. Bucholz EM, Toomey SL, Butala NM, Chien AT, **Yeh RW**, Schuster MA. Suitability of elderly adult hospital readmission rates for profiling readmissions in younger adult and pediatric populations. *Health Serv Res.* 2020 Feb 9. doi: 10.1111/1475-6773.13269. [Epub ahead of print] PMID: 32037552.
227. Faridi KF*, Garratt KN, Kennedy KF, Maddox TM, Secemsky EA, Butala NM, **Yeh RW**. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative. *Circ Cardiovasc Qual Outcomes.* 2020 Mar;13(3):e006275. doi: 10.1161/CIRCOUTCOMES.119.006275. Epub 2020 Mar 11. PMID: 32156164.
228. Wadhwa RK*, Wang Y, Figueroa JF, Dominici F, **Yeh RW**, Joynt Maddox KE. Mortality and Hospitalizations for Dually Enrolled and Nondually Enrolled Medicare Beneficiaries Aged 65 Years or Older, 2004 to 2017. *JAMA.* 2020 Mar 10;323(10):961-969. doi: 10.1001/jama.2020.1021. PMID: 32154858.
229. Kundi H*, Noseworthy PA, Valsdottir LR, Shen C, Yao X, **Yeh RW**, Kramer DB. Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation. *Am J Cardiol.* 2020 Feb 8. pii: S0002-9149(20)30117-X. doi: 10.1016/j.amjcard.2020.01.049 PMID: 32147090.
230. Wadhwa RK*, Bhatt DL, Kind AJH, Song Y, Williams KA, Maddox TM, **Yeh RW**, Dong L, Doros G, Turchin A, Joynt Maddox KE. Association of Outpatient Practice-Level Socioeconomic Disadvantage With Quality of Care and Outcomes Among Older Adults With Coronary Artery Disease: Implications for Value-Based Payment. *Circ Cardiovasc Qual Outcomes.* 2020 Mar 31:CIRCOUTCOMES119005977. doi: 10.1161/CIRCOUTCOMES.119.005977. [Epub ahead of print] PMID: 32228065.

231. Xenogiannis I, Gkargkoulas F, Karpaliotis D, Alaswad K, Jaffer FA, **Yeh RW**, Patel M, Mahmud E, Choi JW, Burke MN, Garcia S, Doing AH, Dattilo P, Toma C, Uretsky B, Krestyaninov O, Khelimskii D, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Russo JJ, Hakemi E, Hall AB, Nikolakopoulos I, Vemmou E, Karatasakis A, Danek B, Rangan BV, Abdullah S, Banerjee S, Brilakis ES. Temporal Trends in Chronic Total Occlusion Percutaneous Coronary Interventions: Insights From the PROGRESS-CTO Registry. *J Invasive Cardiol*. 2020 Mar 20. pii: JIC20200320-3. [Epub ahead of print] PMID: 32198318.
232. Nathan AS, Xiang Q, Wojdyla D, Khatana SAM, Dayoub EJ, Wadhera RK, Bhatt DL, Kolansky DM, Kirtane AJ, Rao SV, **Yeh RW**, Groeneveld PW, Wang TY, Giri J. Performance of Hospitals When Assessing Disease-Based Mortality Compared With Procedural Mortality for Patients With Acute Myocardial Infarction. *JAMA Cardiol*. 2020 Apr 29:e200753. doi: 10.1001/jamacardio.2020.0753. Online ahead of print. PMID: 32347890.
233. Wadhera RK*, Figueroa JF, Joynt Maddox KE, Rosenbaum LS, Kazi DS, **Yeh RW**. Quality Measure Development and Associated Spending by the Centers for Medicare & Medicaid Services. *JAMA*. 2020 Apr 28;323(16):1614-1616. doi: 10.1001/jama.2020.1816. PMID: 32343321.
234. Young MN, Kolte D, Cadigan ME, Laikhter E, Sinclair K, Pomerantsev E, Fifer MA, Sundt TM, **Yeh RW**, Jaffer FA. Multidisciplinary Heart Team Approach for Complex Coronary Artery Disease: Single Center Clinical Presentation. *J Am Heart Assoc*. 2020 Apr 21;9(8):e014738. doi: 10.1161/JAHA.119.014738. Epub 2020 Apr 20. PMID: 32308096.
235. D'Angelo RN, Khanna R, **Yeh RW**, Goldstein L, Kalsekar I, Marcello S, Tung P, Zimetbaum PJ. Trends and predictors of early ablation for Atrial Fibrillation in a Nationwide population under age 65: a retrospective observational study. *BMC Cardiovasc Disord*. 2020 Apr 6;20(1):161. doi: 10.1186/s12872-020-01446-9. PMID: 32252637.
236. Wadhera RK*, Wadhera P, Gaba P, Figueroa JF, Joynt Maddox KE, **Yeh RW**, Shen C. Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs. *JAMA*. 2020 Apr 29:e207197. doi: 10.1001/jama.2020.7197. Online ahead of print. PMID: 32347898 Free PMC article.
237. Vemulapalli S, Prillinger J, Thourani V, **Yeh RW**. Mitral Valve Surgical Volume and Transcatheter Mitral Valve Repair Outcomes: Impact of a Proposed Volume Requirement on Geographic Access. *J Am Heart Assoc*. 2020 May 27:e016140. doi: 10.1161/JAHA.119.016140. PMID: 3245650.
238. Teja B, Raub D, Friedrich S, Rostin P, Patrocínio MD, Schneider JC, Shen C, Brat GA, Houle TT, **Yeh RW**, Eikermann M. Incidence, Prediction, and Causes of Unplanned 30-Day Hospital Admission After Ambulatory Procedures. *Anesth Analg*. 2020 May 14. doi: 10.1213/ANE.0000000000004852. Online ahead of print. PMID: 32427660.
239. Faridi KF*, Tamez H, Strom JB, Song Y, Butala NM, Shen C, Secemsky EA, Mauri L, Curtis JP, Gibson CM, **Yeh RW**. Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. *Circulation*. 2020 Jul 21;142(3):306-308. doi: 10.1161/CIRCULATIONAHA.120.047729. Epub 2020 Jul 20. PMID: 32687440.
240. Berg DD, **Yeh RW**, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL 3rd, Cange AL, Sabatine MS, O'Donoghue ML. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. *J Thromb Thrombolysis*. 2020 Jul 18. doi: 10.1007/s11239-020-02221-5. Online ahead of print. PMID: 32683645.
241. Butala NM*, Strom JB, Faridi KF, Kazi DS, Zhao Y, Brennan JM, Popma JJ, Shen C, **Yeh RW**. Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement. *JACC Cardiovasc Interv*. 2020 Jul 8:S1936-8798(20)30873-6. doi: 10.1016/j.jcin.2020.03.049. Online ahead of print. PMID: 32682677.
242. Nikolakopoulos I, Choi JW, Alaswad K, Khatri JJ, Krestyaninov O, Khelimskii D, **Yeh RW**, Jaffer

FA, Toma C, Patel M, Mahmud E, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Gkargkoulas F, Uretsky B, Sheikh AM, Vemmou E, Xenogiannis I, Rangan BV, Garcia S, Abdullah S, Banerjee S, Burke MN, Brilakis ES, Karpaliotis D. Equipment utilization in chronic total occlusion percutaneous coronary interventions: Insights from the PROGRESS-CTO registry. *Catheter Cardiovasc Interv*. 2020 Jun 29. doi: 10.1002/ccd.29106. Online ahead of print. PMID: 32597031.

243. Khatana SAM, Wadhera RK, Choi E, Groeneveld PW, Culhane DP, Kushel M, Kazi DS, **Yeh RW**, Shen C. Association of Homelessness with Hospital Readmissions-an Analysis of Three Large States. *J Gen Intern Med*. 2020 Jun 17. doi: 10.1007/s11606-020-05946-4. Online ahead of print. PMID: 32556872.
244. Fazel R, Joseph TI, Sankardas MA, Pinto DS, **Yeh RW**, Kumbhani DJ, Nallamothu BK. Comparison of Reperfusion Strategies for ST-Segment-Elevation Myocardial Infarction: A Multivariate Network Meta-analysis. *J Am Heart Assoc*. 2020 Jun 16;9(12):e015186. doi: 10.1161/JAHA.119.015186. Epub 2020 Jun 5. PMID: 32500800.
245. Butala NM*, Chung M, Secemsky EA, Manandhar P, Marquis-Gravel G, Kosinski AS, Vemulapalli S, **Yeh RW**, Cohen DJ. Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Variation in Practice and Outcomes. *JACC Cardiovasc Interv*. 2020 Jun 8;13(11):1277-1287. doi: 10.1016/j.jcin.2020.03.008. PMID: 32499018.
246. Strom JB*, Faridi KF, Butala NM, Zhao Y, Tamez H, Valsdottir LR, Brennan JM, Shen C, Popma JJ, Kazi DS, **Yeh RW**. Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement: Findings From the EXTEND Study. *Circulation*. 2020 Jul 21;142(3):203-213. doi: 10.1161/CIRCULATIONAHA.120.046159. Epub 2020 May 21. PMID: 32436390.

Other Peer-Reviewed Publications

1. **Yeh RW**, Jang IK. Argatroban: Update. *American Heart Journal*. (Review) 2006 Jun;151(6):1131-8
2. Pellegrini CN, **Yeh RW**, Olgin J, Lee BK. Episodic ventricular pacing with intact atrioventricular nodal function in a DDDR device: what is the rhythm and how can it be prevented? *Heart Rhythm*. 2008 Jun;5(6):897-8.
3. DeFaria Yeh D, Lu J, Kim A, **Yeh RW**, Scheinman M. Calcium-triggered short-coupled polymorphous ventricular tachycardia. *Pacing and Clinical Electrophysiology*. 2010 Jan;33(1):117-22.
4. **Yeh RW**, Go AS. Rethinking the epidemiology of acute myocardial infarction: challenges and opportunities. *Archives of Internal Medicine*. (Review) 2010 May 10;170(9):759-64.
5. **Yeh RW**, Yu PB, Drachman DE. Takotsubo cardiomyopathy complicated by cardiac tamponade: classic hemodynamic findings with a new disease. *Circulation*. 2010 September 21;122:1239-1241.
6. Suh WM, **Yeh RW**, Watkins MT, Palacios IF. Inadvertent femoral endarterectomy: a complication from a suture-based vascular closure device. *Journal of Vascular Access*. 2011;12(1):71-2.
7. Shahian DM, Meyer GS, **Yeh RW**, Fifer MA, Torchiana DF. Percutaneous coronary intervention without on-site cardiac surgical backup. (Review) *New England Journal of Medicine*. 2012 May 10;366:1814-23. PMID: 22571203.
8. Wimmer N*, **Yeh RW**. Another view of personalized medicine: optimizing stent selection on the basis of predicted benefit in percutaneous coronary intervention. (Review) *Trends in Cardiovascular Medicine*. 2012 Jan;22(1):23-8. PMID: 22841840.
9. Vardi M, **Yeh RW**, Herzog CA, Winkelmayr WC, Setoguchi S, Charytan DM. Strategies for Postmarketing Surveillance of Drugs and Devices in Patients with ESRD Undergoing Dialysis. *Clin J Am Soc Nephrol*. 2013 Dec;8(12):2213-20. PMID: 23970129.

10. Hawkins BM*, Fitzgerald-McKeon L, **Yeh RW**. High risk PCI in the era of public reporting: clinical and ethical considerations in the care of an elderly patient with critical left main disease and shock. *Circulation*. 2014 Jan 14;129(2):258-65. PMID: 24421361.
11. Czarny MJ, Nathan AS, **Yeh RW**, Mauri L. Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. *Clin Cardiol*. 2014 May 2. doi: 10.1002/clc.22289.
12. Young MN*, **Yeh RW**. Public reporting and coronary revascularization: risk and benefit. *Coron Artery Dis*. 2014 Nov;25(7):619-26. doi: 10.1097. PMID: 25248138.
13. Wasfy JH*, Borden WB, Secemsky EA, McCabe JM, **Yeh RW**. Public Reporting in Cardiovascular Medicine - Accountability, Unintended Consequences, and Promise for Improvement. *Circulation*. 2015 Apr 28;131(17):1518-27. PMID: 25918041.
14. Wasfy JH*, **Yeh RW**. Future of the PCI Readmission Metric. *Circ Cardiovasc Qual Outcomes*. 2016 Mar;9(2):186-9. PMID: 26812931.
15. Tahir U*, **Yeh RW**. Duration of dual antiplatelet therapy (DAPT): a call for personalized medicine. *J Thorac Dis*. 2016 Oct;8(10):E1226-E1229. PMID: 27867593.
16. Gupta A, **Yeh RW**, Tamis-Holland JE, Patel SH, Guyton RA, Klein LW, Rab T, Kirtane AJ. Implications of Public Reporting of Risk-Adjusted Mortality Following Percutaneous Coronary Intervention: Misperceptions and Potential Consequences for High-Risk Patients Including Nonsurgical Patients. *JACC Cardiovasc Interv*. 2016 Oct 24;9(20):2077-2085. doi: 10.1016/j.jcin.2016.08.012. Review. PMID: 27765301.
17. Kalra A, Rehman H, Khera S, Thyagarajan B, Bhatt DL, Kleiman NS, **Yeh RW**. New-Generation Coronary Stents: Current Data and Future Directions. *Curr Atheroscler Rep*. 2017 Mar;19(3):14. doi: 10.1007/s11883-017-0654-1. Review. PMID: 28220461.
18. **Yeh RW**, Kramer DB. Decision Tools to Improve Personalized Care in Cardiovascular Disease: Moving the Art of Medicine Toward Science. *Circulation*. 2017 Mar 21;135(12):1097-1100. doi: 10.1161/CIRCULATIONAHA.116.024247. PMID: 28320801.
19. Nathan AS*, Sen S, **Yeh RW**. The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. *Expert Opin Drug Saf*. 2017 Apr 7. doi: 10.1080/14740338.2017.1315101. [Epub ahead of print] PMID: 28387542
20. Partida RA*, **Yeh RW**. Contemporary Drug-Eluting Stent Platforms: Design, Safety, and Clinical Efficacy. *Cardiol Clin*. 2017 May;35(2):281-296. doi: 10.1016/j.ccl.2016.12.010. PMID: 28411902.
21. Tahir UA*, **Yeh RW**. Individualizing dual antiplatelet therapy duration after percutaneous coronary intervention: from randomized control trials to personalized medicine. *Expert Rev Cardiovasc Ther*. 2017 Sep;15(9):681-693. doi: 10.1080/14779072.2017.1362980. Epub 2017 Aug 9. PMID: 28764572.
22. Wadhwa RK*, Anderson JD, **Yeh RW**. High-Risk Percutaneous Coronary Intervention in Public Reporting States: the Evidence, Exclusion of Critically Ill Patients, and Implications. *Curr Heart Fail Rep*. 2017 Dec;14(6):514-518. doi: 10.1007/s11897-017-0369-1. Review. PMID: 29101664.
23. Weintraub WS, **Yeh RW**. Challenges of Assessing Therapeutic or Diagnostic Outcomes with Observational Data. *Am J Med*. 2018 Feb;131(2):206-210. doi: 10.1016/j.amjmed.2017.10.027. Epub 2017 Dec 11. No abstract available. PMID: 29103925.
24. Wadhwa RK*, **Yeh RW**, Joynt Maddox KE. The Rise and Fall of Mandatory Cardiac Bundled Payments. *JAMA*. 2018 Jan 23;319(4):335-336. doi: 10.1001/jama.2017.19205. No abstract available. PMID: 29327034.
25. Vidula MK*, Secemsky EA, **Yeh RW**. Duration of dual antiplatelet therapy for stented patients: An

update for the clinician. *Prog Cardiovasc Dis*. 2018 Feb 1. pii: S0033-0620(18)30023-9. doi: 10.1016/j.pcad.2018.01.006. [Epub ahead of print] Review. PMID: 29409813.

26. Yang JX*, **Yeh RW**. Safety and effectiveness of zotarolimus-eluting stents for percutaneous coronary intervention: a systematic review. *Future Cardiol*. 2018 Feb 16. doi: 10.2217/fca-2017-0091. [Epub ahead of print] PMID: 29448810.
27. Wadhwa RK*, Joynt Maddox KE, **Yeh RW**, Bhatt DL. Public Reporting of Percutaneous Coronary Intervention Outcomes: Moving Beyond the Status Quo. *JAMA Cardiol*. 2018 May 9. doi: 10.1001/jamacardio.2018.0947. [Epub ahead of print] PMID: 29800962.
28. Raber I*, McCarthy CP, **Yeh RW**. Health Insurance and Mobile Health Devices: Opportunities and Concerns. *JAMA*. 2019 May 14;321(18):1767-1768. doi: 10.1001/jama.2019.3353. No abstract available. PMID: 30973573.
29. Rajan PV, Holtzman JN, Kesselheim AS, **Yeh RW**, Kramer DB. Landscape of Cardiovascular Device Registries in the United States. *J Am Heart Assoc*. 2019 Jun 4;8(11):e012756. doi: 10.1161/JAHA.119.012756. Epub 2019 Jun 1. PMID: 31433706.

Non-Peer Reviewed Publications in Print or Other Media

Reviews, Chapters, Monographs and Editorials

1. Sakhuja, R, **Yeh RW**, Bhatt DL. Antiplatelet agents in acute coronary syndromes. *Current Problems in Cardiology*. (Review) 2010;35:123-170.
2. **Yeh RW**, Go AS. Recent epidemiologic trends in the incidence of myocardial infarction: what have we learned? *Interventional Cardiology*. (Review) October 2010, Vol. 2, No. 5, Pages 623-626.
3. Sakhuja R, **Yeh RW**, Bhatt DL. Anticoagulant agents in acute coronary syndromes. *Current Problems in Cardiology*. (Review) 2011;36:127-68.
4. **Yeh RW**, Mauri L. Choosing methods to minimize confounding in observational studies: do the ends justify the means? *Circulation: Cardiovascular Quality and Outcomes*. 2011 Nov 1;4(6):581-3.
5. Kunz LM, **Yeh RW**, Normand ST. Comparative effectiveness research: does one size fit all? *Statistics in Medicine*. 2012 Nov 10;31(25):3062-5
6. **Yeh RW**. Bypass yielded higher reintervention rates than stenting in PAD: perspective. *Cardiology today's Intervention*. 2013 September/October:28
7. Potter BJ, **Yeh RW**, Pinto D. Public Reporting of PCI Outcomes: For Better or for Worse. *S.Curr Cardiol Rep*. 2014 Jul;16(7):500. doi: 10.1007/s11886-014-0500-9.
8. **Yeh RW**, Wimmer NJ*. Blood transfusion in myocardial infarction: opening old wounds for comparative-effectiveness research. *J Am Coll Cardiol*. 2014 Aug 26;64(8):820-2. PMID: 25145527
9. Baron SJ*, **Yeh RW**, Cohen DJ. The challenges of success: Maintaining access to high quality PCI in the face of declining procedural volumes. *Circulation*. 2014 Oct 14;130(16):1343-5. PMID: 25189216
10. **Yeh RW**, Mauri L, Kereiakes D. Dual antiplatelet therapy duration following coronary stenting. *Journal of the American College of Cardiology*. 2015 Mar 3;65(8):787-90. PMID: 25720621
11. **Yeh RW**, Cohen DJ, Mauri L. Close encounters with errors of the second kind: evaluating the risks and benefits of long-term dual antiplatelet therapy. *European Heart Journal*. 2015 May 21;36(20):1216-8. PMID: 25796054.

12. Mauri L, **Yeh RW**, Kereiakes DJ. Duration of dual antiplatelet therapy after drug-eluting stents. *New England Journal of Medicine*. 2015 Apr 2;372(14):1373-4. PMID: 25830429
13. **Yeh RW**, Elmariah S, Doros G, Kereiakes DJ, Mauri L. Dual antiplatelet therapy duration and mortality – the Authors' Reply. *Lancet*. 2015 May 30;385(9983):2149-50.
14. Butala N*, **Yeh RW**. Is Door-to-Balloon Time a Misleading Metric? [June 4, 2015]. http://www.acc.org/latest-in-cardiology/articles/2015/06/03/13/23/is-door-to-balloon-time-a-misleading-metric?w_nav=LC.
15. Chang L, **Yeh RW**. Assessing the optimal strategy for dual antiplatelet therapy. *Expert Rev Cardiovasc Ther*. 2015 Jul 29;1-3. PMID: 26224530
16. **Yeh RW**, Kereiakes DJ, Mauri L. Reply: Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities. *J Am Coll Cardiol*. 2015 Sep 8;66(10):1204-5. PMID: 26338005
17. Waldo SW*, Secemsky EA, O'Brien C, Kennedy KF, Pomerantsev E, Sundt TM 3rd, McNulty EJ, Scirica BM, **Yeh RW**. Response to Letter Regarding Article, "Surgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention". *Circulation*. 2015 Sep 22;132(12):e156. doi: 10.1161/CIRCULATIONAHA.115.016777. PMID: 26391303
18. **Yeh RW**, Kereiakes DJ, Mauri L. Reply: Analysis of Dual Antiplatelet Therapy. *J Am Coll Cardiol*. 2015 Nov 3;66(18):2056. PMID: 26516012
19. **Yeh RW**, Elmariah S, Doros G, Kereiakes DJ, Mauri L. Mortality risk with dual antiplatelet therapy? *Lancet*. 2015 Oct 17;386(10003):1533-4. PMID: 26530618.
20. Kramer DB, **Yeh RW**, Zimetbaum PJ. Hard questions for mobile technology in cardiology. *Trends Cardiovasc Med*. 2016 May;26(4):387-8. PMID: 26919932.
21. **Yeh RW**, Kirtane AJ, Rao SV. Incentivizing Transradial Access for Primary Percutaneous Coronary Intervention While Maintaining Timely Reperfusion. *JAMA Cardiol*. 2017 Aug 16. doi: 10.1001/jamacardio.2017.2348. [Epub ahead of print]. PMID: 28813548.
22. Secemsky EA*, **Yeh RW**. Brachial-ankle pulse wave velocity as a marker of adverse events following non-ST-elevation myocardial infarction: a new standard in risk stratification? *Coron Artery Dis*. 2017 Aug 18. doi: 10.1097/MCA.0000000000000548. [Epub ahead of print]. PMID: 28825931.
23. Feldman DN, **Yeh RW**. Public Reporting of Percutaneous Coronary Intervention Mortality in New York State: Are We Helping Our Patients? *Circ Cardiovasc Qual Outcomes*. 2017 Sep;10(9). pii: e004027. doi: 10.1161/CIRCOUTCOMES.117.004027. PMID: 28893834.
24. Wasfy JH*, **Yeh RW**. Understanding How to Improve Quality and Value for Patients With Acute Myocardial Infarction. *JAMA Cardiol*. 2017 Dec 20. doi: 10.1001/jamacardio.2017.4779. [Epub ahead of print] No abstract available. PMID: 29261834.
25. Strom JB*, **Yeh RW**. Should We Care About Short-Term Readmissions After Percutaneous Coronary Intervention? *Circ Cardiovasc Interv*. 2017 Dec;10(12). pii: e006123. doi: 10.1161/CIRCINTERVENTIONS.117.006123. No abstract available. PMID: 29246919
26. Faridi KF*, **Yeh RW**. Risk score identifies patients who will benefit from prolonged dual antiplatelet therapy. *BMJ Evid Based Med*. 2018 Apr;23(2):73-74. doi: 10.1136/bmjebm-2017-110822. Epub 2018 Feb 19. Review. PMID: 29595135.
27. **Yeh RW**. Academic Cardiology and Social Media: Navigating the Wisdom and Madness of the Crowd. *Circ Cardiovasc Qual Outcomes*. 2018 Apr;11(4):e004736. doi: 10.1161/CIRCOUTCOMES.118.004736. PMID 29650720.

28. Secemsky EA*, Shen C, **Yeh RW**. Exposure Misclassification in Observational Studies: Setting New Standards. *Circ Cardiovasc Qual Outcomes*. 2018 Jul;11(7):e004939. doi: 10.1161/CIRCOUTCOMES.118.004939. PMID: 29991648
29. Wadhwa RK*, **Yeh RW**. Inadequate Surrogates for Imperfect Quality Measures. *Circ Cardiovasc Interv*. 2018 Sep;11(9):e007216. doi: 10.1161/CIRCINTERVENTIONS.118.007216. PMID: 30354606.
30. Wadhwa RK*, Joynt Maddox KE, **Yeh RW**. Did This Health Care Policy Do Harm? *New York Times*. December 21, 2018.
31. Secemsky EA*, Carroll BJ, **Yeh RW**. Inferior Vena Cava Filters and Mortality: Is It the Underlying Process, the Patient, or the Device? *JAMA Netw Open*. 2018 Jul 6;1(3):e180453. doi: 10.1001/jamanetworkopen.2018.0453. PMID: 30646019.
32. Strom JB*, Shen C, **Yeh RW**. SCOT-HEART: Does it live up to the PROMISE? *J Cardiovasc Comput Tomogr*. 2019 Jan 4. pii: S1934-5925(18)30530-6. doi: 10.1016/j.jcct.2019.01.008. PMID: 30638707.
33. Faridi KF*, **Yeh RW**, Poulin MF. Treating Symptomatic Aortic Stenosis With Transcatheter Aortic Valve Replacement: Is There Time to Wait? *J Am Heart Assoc*. 2019 Jan 8;8(1):e011527. doi: 10.1161/JAHA.118.011527. PMID: 30612523.
34. Wadhwa RK*, **Yeh RW**, Joynt Maddox KE. The Hospital Readmissions Reduction Program - Time for a Reboot. *N Engl J Med*. 2019 Jun 13;380(24):2289-2291. doi: 10.1056/NEJMp1901225. Epub 2019 May 15. PMID: 31091367.
35. Strom JB*, **Yeh RW**. Putting Theory to the Test. *Circ Cardiovasc Interv*. 2019 May;12(5):e007953. doi: 10.1161/CIRCINTERVENTIONS.119.007953. No abstract available. PMID: 31084240.
36. **Yeh RW**, Nathan AS. Paving a Road to PCI Quality With Good Intentions and Rigorous Statistics: Still Not Enough? *JACC Cardiovasc Interv*. 2019 Oct 14;12(19):1976-1978. doi: 10.1016/j.jcin.2019.08.012. No abstract available. PMID: 31601392.
37. Riley RF, **Yeh RW**. Myocardial Perfusion After Coronary Chronic Total Occlusion Percutaneous Coronary Intervention: Does It Matter to Myocytes How You Cross the Lesion? *Circ Cardiovasc Interv*. 2019 Nov;12(11):e008568. doi: 10.1161/CIRCINTERVENTIONS.119.008568. Epub 2019 Nov 1. No abstract available. PMID: 31672033.
38. Mihatov N*, **Yeh RW**. Short DAPT duration after ACS - not for the faint of heart. *EuroIntervention*. 2019 Dec 6;15(11):e943-e944. doi: 10.4244/EIJV15I11A175. No abstract available. PMID: 31806581.
39. Kramer DB, Kazi DS, **Yeh RW**. Equipose on COVID-19 therapeutics. *BMJ Opinion*. April 7, 2020.

Books/Textbooks for the Medical or Scientific Community

1. **Yeh RW**, Coen D. Pharmacology of viral replication. Chapter in textbook by Golan, DE et al. *Principles of Pharmacology*. Lippincott Williams & Wilkins. 2005, 2007.
2. **Yeh RW**, Wimmer NJ*. Design, analysis, and interpretation of comparative effectiveness studies and randomized clinical trials of coronary stents. Chapter in text by Price, MJ. *Coronary stenting*. Saunders. 2014.
3. Calfon MA*, **Yeh RW**. Balloons and balloon angioplasty. Chapter in *American College of Cardiology Self-Assessment Program: CathSAP4*. 2013.
4. Monteleone P*, Yeh RW. Unstable Angina/NSTEMI: Myocardial Infarction Pathophysiology. Chapter in *American College of Cardiology Self-Assessment Program: ACCSAP9* 2015.

5. Section Editor. Brilakis E. Manual of Chronic Total Occlusion Interventions, 2nd Edition. Academic Press. 2017.
6. Tamez H*, **Yeh RW**. Balloons and balloon angioplasty. Chapter in American College of Cardiology Cath Self-Assessment Program: CathSAP5. 2015.
7. Ferro EG*, **Yeh RW**. Optimizing DAPT duration after PCI: from randomized controlled trials to individualized net clinical benefit. Chapter in Clopidogrel and the Newer P2Y₁₂ Antiplatelet Agents. Nova Science Publishers 2018.
8. Miller MM*, **Yeh RW**. Balloons and balloon angioplasty. Chapter in American College of Cardiology Cath Self-Assessment Program: CathSAP6. 2018.
9. Kellogg, M*, Yeh RW. Balloons and balloon angioplasty. In Cardiac Catheterization & Interventional Cardiology Self-Assessment Program (CathSAP). Washington, DC: American College of Cardiology Foundation; 2020. Available at: www.acc.org/cathsap.

Letters to the Editor

1. Rassi AN*, **Yeh RW**. Cardiovascular events risk after noncardiac surgery. JAMA. 2014 Feb 5;311(5):525.
2. **Yeh RW**, Wimmer NJ*. Reply: Letter to the editor regarding article "Comparison of Transradial Versus Transfemoral Percutaneous Coronary Intervention in Routine Practice: Evidence for the Importance of "Falsification Hypotheses" in Observational Studies of Comparative Effectiveness". J Am Coll Cardiol. 2014 Mar 13. pii: S0735-1097(14)01519-8. doi: 10.1016/j.jacc.2014.02.570.
3. **Yeh RW**, Elmariah S, Doros G, Kereiakes DJ, Mauri L. Dual antiplatelet therapy duration and mortality - Authors' reply. Lancet. 2015 May 30;385(9983):2149-50. PMID: 26068262.
4. Wasfy JH*, Dominici F, **Yeh RW**. Letter by Wasfy et al Regarding Article, "Facility Level Variation in Hospitalization, Mortality, and Costs in the 30 Days After Percutaneous Coronary Intervention: Insights on Short-Term Healthcare Value From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System (VA CART) Program". Circulation. 2016 Feb 2;133(5):e376. PMID: 26831441.
5. Secemsky EA*, Wimmer NJ, **Yeh RW**. Letter by Secemsky et al Regarding Article, "Relationship Between Femoral Vascular Closure Devices and Short-Term Mortality From 271 845 Percutaneous Coronary Intervention Procedures Performed in the United Kingdom Between 2006 and 2011: A Propensity Score-Corrected Analysis From the British Cardiovascular Intervention Society". Circ Cardiovasc Interv. 2016 Sep;9(9). pii: e004262. doi: 10.1161/CIRCINTERVENTIONS.116.004262. No abstract available. PMID: 27630028.
6. Giri J*, **Yeh RW**. The Effect of Survivor Bias on Observational Analyses of Staged PCI in STEMI Patients. JACC Cardiovasc Interv. 2017 Mar 27;10(6):629-630. doi: 10.1016/j.jcin.2017.01.019. No abstract available. PMID: 28335905.
7. Secemsky EA*, **Yeh RW**. Complete vs Incomplete Revascularization During Percutaneous Coronary Intervention and Improved Survival-The Key Is Immortality. JAMA Cardiol. 2018 Mar 28. doi: 10.1001/jamacardio.2018.0078. [Epub ahead of print] No abstract available. PMID: 29590282.
8. Secemsky EA*, **Yeh RW**. Re. Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction with Cardiogenic Shock. Epidemiology. 2018 Jun 27. doi: 10.1097/EDE.0000000000000884. PMID: 29958193.
9. Kundi H, Yeh RW. Reply: Trends in Isolated Surgical Aortic Valve Replacement. JACC Cardiovasc Interv. 2019 Jan 14;12(1):108-109. doi: 10.1016/j.jcin.2018.11.002. PMID: 30621970.

10. Yeh RW, Kereiakes DJ, Secemsky EA, Steg PG, Mauri L. The DAPT Score in Sweden: Successful Validation, Flawed Interpretation. *J Am Coll Cardiol*. 2019 Jan 8;73(1):113-114. doi: 10.1016/j.jacc.2018.10.053. PMID: 30621941
11. Ferro EG, Wadhwa RK, Yeh RW. Readmission Penalties: The Authors Reply. *Health Aff (Millwood)*. 2019 Aug;38(8):1410. doi: 10.1377/hlthaff.2019.00689. No abstract available. PMID: 31381413.
12. Cepas-Guillen P, Vásquez S, Fernandez-Valledor A, San Antonio R, Flores-Umanzor E, Martin-Yuste V, Xenogiannis I, Karpaliotis D, Alaswad K, Basir MB, **Yeh RW**, Tamez H, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Khatri JJ, Sheikh AM, Malik BA, Greene ME, Abi Rafeh N, Maalouf A, Abou Jaoudeh F, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Gkargkoulas F, Russo J, Hakemi E, Tajti P, Hall AB, Vemmou E, Nikolakopoulos I, Rangan BV, Abdullah S, Banerjee S, Brilakis ES. A Need For Long-Term Results of LMCA-CTO-PCI. *J Invasive Cardiol*. 2019 Nov;31(11):E342. PMID: 31671069.
13. Reynolds MR, Kramer DB, **Yeh RW**, Cohen DJ. AF Ablation Outcomes: Real World or Fun House Mirror? *J Am Coll Cardiol*. 2020 Mar 17;75(10):1243. doi: 10.1016/j.jacc.2019.11.068. PMID: 32164902
14. Wadhwa RK, **Yeh RW**, Joynt Maddox KE. Database Inaccuracies and Disparities in Care Among Homeless Adults Hospitalized for Cardiovascular Conditions-Reply. *JAMA Intern Med*. 2020 Apr 1;180(4):614-615. doi: 10.1001/jamainternmed.2020.0021. PMID: 32250403.

Clinical Guidelines and Reports

1. Katzan IL, Spertus J, Bettger JP, Bravata DM, Reeves MJ, Smith EE, Bushnell C, Higashida RT, Hinchey JA, Holloway RG, Howard G, King RB, Krumholz HM, Lutz BJ, **Yeh RW**; on behalf of the American Heart Association Stroke Council, Council on Quality of Care and Outcomes Research, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia, and Council on Clinical Cardiology. Risk adjustment of ischemic stroke outcomes for comparing hospital performance: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014 Mar;45(3):918-44. PMID: 24457296.
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, **Yeh RW**, Turner MB. Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association. *Circulation*. 2015 Jan 27;131(4):434-41. PMID: 25623128.
3. Klein LW, Harjai KJ, Resnic F, Weintraub WS, Anderson HV, **Yeh RW**, Feldman DN, Gigliotti OS, Rosenfeld K, Duffy P. 2016 Revision of the SCAI Position Statement on Public Reporting. *Catheter Cardiovasc Interv*. 2016 Oct 18. doi: 10.1002/ccd.26818. [Epub ahead of print] PMID: 27755653.
4. Riley RF, Henry TD, Mahmud E, Kirtane AJ, Brilakis ES, Goyal A, Grines CL, Lombardi WL, Maran A, Rab T, Tremmel JA, Truesdell AG, **Yeh RW**, Zhao DX, Jaffer FA. SCAI Position Statement on Optimal Percutaneous Coronary Interventional Therapy for Complex Coronary Artery Disease. *Catheter Cardiovasc Interv*. 2020 May 14. doi: 10.1002/ccd.28994. Online ahead of print. PMID: 32406991.

NARRATIVE REPORT

My work combines clinical expertise and teaching in cardiovascular procedures with an investigational focus on studying how we can more effectively and efficiently use data to evaluate the efficacy of interventions intended to improve cardiovascular care. My clinical, educational and investigational activities are this intimately tied to one another. I currently spend 60% of my time conducting clinical research, 30% of my time dedicated to clinical service, 10% of time split among teaching and administrative activities. My primary investigational work has focused on modernizing empiricism in cardiovascular care – that is, how can we improve the ways knowledge on the safety and effectiveness of medical interventions is generated. My primary clinical achievements to date have been the creation of two nationally recognized programs in the treatment of coronary chronic total occlusion (first at the Massachusetts General Hospital and later at Beth Israel Deaconess Medical Center), including performing the first planned antegrade-dissection reentry recanalization of an occluded artery in the metro Boston area, and performing the first retrograde recanalization of an occluded coronary artery in Massachusetts.

Area of Excellence – Investigation

My investigational activities focus developing better approaches for evaluating medical interventions in cardiovascular care, and building strategies to improve the value of these interventions in contemporary clinical practice. In addressing contemporary practice, research from my group is built on broadly inclusive populations that reflects the diversity of patients that may not be represented in traditional randomized trials – to that end I focus on using large observational datasets as well as pragmatic clinical trial designs.

Cardiovascular Prediction and Comparative Effectiveness Research: My research has resulted in seminal contributions to the field of cardiovascular outcomes research. I have led several studies that leverage data from administrative claims and electronic medical records to study population-based cardiovascular epidemiology. These methods of utilizing health plan and claims data have advanced the ability to make inferences regarding population epidemiology in a timely and efficient manner. The research has resulted in the first description of the rapidly changing epidemiology of myocardial infarction (NEJM 2010), as well as declines in the use of nuclear perfusion imaging in California (JAMA 2014) and coronary revascularization in Massachusetts (JAMA Internal Medicine 2014). I have also led the creation of multiple risk-adjustment models that have been used in more than 200 US hospitals to help assess hospital quality (JACC 2012, JAHA 2014, Circulation Quality and Outcomes, 2013), and performed the first application of econometric methods of instrumental variables and falsification hypotheses in cardiovascular device research (BMC Medicine 2011, Circ Quality and Outcomes 2013, JACC 2013). I was asked to lead a workshop on these methods at the US Food and Drug Administration to introduce these methods to the statistical group at the Centers for Device and Radiologic Health, and serve as a Special Employee to the FDA's Cardiac Devices Advisory Group. These methods have since been increasingly adopted and are now considered best practice in medical device observational research. I am the Co-Principal Investigator (with my mentee Dr. Eric Secemsky) of the Safety Assessment of Femoropopliteal Endovascular treatment with Paclitaxel-coated Devices (SAFE-PAD) Study (NCTNCT04496544), a multi-industry sponsored post-market safety evaluation that was designed in collaboration with the FDA to evaluate an emerging safety signal for these devices. SAFE PAD is the first pre-specified observational analysis using administrative claims data used to support device safety evaluation in a regulatory context.

Enhancing Clinical Trial Methods: I have further worked in the field of pragmatic clinical trial design to identify optimal methods of treatment of coronary artery disease. I was one of the lead investigators for the Dual Antiplatelet Therapy Study, an international multicenter study comparing 12 vs. 30 months of dual antiplatelet therapy after coronary stenting, sponsored jointly by the NIH, the Food and Drug-Administration, and industry, and published in the New England Journal. The study was the

largest randomized trial of coronary intervention to date, and utilized a streamlined efficient design to decrease costs and enhance enrollment. In addition, through the application of prediction modeling to the secondary analysis of randomized trials, I led the development of a decision tool to deliver personalized treatment strategies for dual antiplatelet therapy after coronary stenting (the DAPT Score), published in JAMA (> 500 citations). This decision tool was incorporated into national guidelines, and the application and web calculator have been used more than 100 countries worldwide. I serve as the Principal Investigator of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study sponsored by the NHLBI, which has demonstrated that administrative claims data can serve as valid alternatives to adjudicated endpoints in large pivotal randomized trials (Circulation, 2020).

Cardiovascular Health Policy Evaluation: I have led a number of evaluations of regional and national health policies that have influenced cardiovascular care, including a series of studies evaluating the unintended consequences of public reporting of cardiovascular procedural outcomes (Circulation, 2014; JACC 2015; JAMA Cardiology 2016, Circulation 2017). I was senior author (working with my mentees Dr. Jason Wasfy and Dr. Rishi Wadhera) of a number of studies evaluating the unintended consequences of the Hospital Readmissions Reduction Policy. (Annals of Internal Medicine, 2017, JAMA 2018, BMJ 2019) These studies have led to reevaluations of the effectiveness of such policies in the cardiovascular and health policy communities.

Overall, I have authored more than 200 peer-reviewed original research manuscripts, and more than 80 as either first-author or senior corresponding author working with trainees. I have been recognized among an international group of my peers, having been awarded the Thomas J. Linnemeier Young Investigator Award at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in 2011 and the Young Physician Scientist Award by the American Society of Clinical Investigation in 2015. Since the Fall of 2015, I have served as the Founding Director of the Richard and Smith Center for Outcomes Research in Cardiology, directing a multimillion dollar research budget and a team of 10 clinical investigators, 6 statisticians, and several trainees. I have served as primary mentor for more than 20 research trainees, 3 as primary mentor on NHLBI-supported K23 award and many of whom have gone on to establish research careers in academic medical centers, and received the HMS Young Mentor Award in 2018.

Area of Excellence – Clinical Innovation

I co-founded the MGH Chronic Total Occlusion PCI program, specializing in complex coronary intervention. With my partner Dr. Farouc Jaffer, we were the first Boston-area interventionalists to perform retrograde and antegrade dissection reentry CTO PCI procedures. Our program was considered the leading center for CTO PCI in New England, and has been recognized in national meetings for interventional cardiologists. I am a participant in the Progress CTO Multicenter registry, limited to high volume expert centers in the US, and have served on the steering committee of a number of clinical trials of complex PCI. Since 2015, I have served as the Director of the Chronic Total Occlusion Intervention Program at the BIDMC, and more recently since 2017, the Director of Complex Coronary Intervention, and Associate Chief of Interventional Cardiology. As a clinical proctor I, have been invited to more than 10 hospitals nationally to train physicians to perform complex coronary procedures. I have given a large number of invited presentations on complex coronary procedures of national scientific and professional society meetings.

Teaching and Education

As an interventional cardiologist, every procedure I have been involved with clinical and procedural teaching of general and interventional cardiology fellows both at the MGH previously and now at BIDMC. At MGH, I gave 1-2 lectures per year to the general cardiology fellows on coronary angiography, and 12 lectures per year to medical residents rotation through the coronary care unit for

the past 5 years. I attended on the cardiology consult service and in the CCU, teaching fellows, residents and medical students, and I supervised general cardiology fellows clinic several afternoons per year. At the BIDMC, I supervise interventional cardiology trainees for each procedure, and teach during weekly catheterization conferences.